A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.
A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation.
Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.
The natural enzymatic dissolution of FIBRIN.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
Important modulators of the activity of plasminogen activators. The inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
An extracellular receptor specific for UROKINASE-TYPE PLASMINOGEN ACTIVATOR. It is attached to the cell membrane via a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE and plays a role in the co-localization of urokinase-type plasminogen activator with PLASMINOGEN.
Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.
Proteins prepared by recombinant DNA technology.
A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain.
Formation or presence of a blood clot (THROMBUS) in a blood vessel within the SKULL. Intracranial thrombosis can lead to thrombotic occlusions and BRAIN INFARCTION. The majority of the thrombotic occlusions are associated with ATHEROSCLEROSIS.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
Injections made into a vein for therapeutic or experimental purposes.
Formation and development of a thrombus or blood clot in the blood vessel.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Elements of limited time intervals, contributing to particular results or situations.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.
A ZINC-dependent carboxypeptidase primary found in the DIGESTIVE SYSTEM. The enzyme catalyzes the preferential cleavage of a C-terminal peptidyl-L-lysine or arginine. It was formerly classified as EC 3.4.2.2 and EC 3.4.12.3.
Blocking of a blood vessel in the SKULL by an EMBOLUS which can be a blood clot (THROMBUS) or other undissolved material in the blood stream. Most emboli are of cardiac origin and are associated with HEART DISEASES. Other non-cardiac sources of emboli are usually associated with VASCULAR DISEASES.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Disease having a short and relatively severe course.
Restoration of blood supply to tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. It is primarily a procedure for treating infarction or other ischemia, by enabling viable ischemic tissue to recover, thus limiting further necrosis. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing REPERFUSION INJURY.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
A protease nexin and serpin subtype that is specific for several SERINE PROTEASES including UROKINASE; THROMBIN; TRYPSIN; and PLASMINOGEN ACTIVATORS.
Bleeding from the vessels of the retina.
A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.
Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
Triple-looped protein domains linked by disulfide bonds. These common structural domains, so-named for their resemblance to Danish pastries known as kringlers, play a role in binding membranes, proteins, and phospholipids as well as in regulating proteolysis. Kringles are also present in coagulation-related and fibrinolytic proteins and other plasma proteinases.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
Component of the NATIONAL INSTITUTES OF HEALTH. It supports and conducts research, both basic and clinical, on the normal and diseases nervous system. It was established in 1950.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures.
The use of focused, high-frequency sound waves to produce local hyperthermia in certain diseased or injured parts of the body or to destroy the diseased tissue.
A metallocarboxypeptidase that removes C-terminal lysine and arginine from biologically active peptides and proteins thereby regulating their activity. It is a zinc enzyme with no preference shown for lysine over arginine. Pro-carboxypeptidase U in human plasma is activated by thrombin or plasmin during clotting to form the unstable carboxypeptidase U.
The rate dynamics in chemical or physical systems.
Blood clot formation in any part of the CAROTID ARTERIES. This may produce CAROTID STENOSIS or occlusion of the vessel, leading to TRANSIENT ISCHEMIC ATTACK; CEREBRAL INFARCTION; or AMAUROSIS FUGAX.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
A blood plasma glycoprotein that mediates cell adhesion and interacts with proteins of the complement, coagulation, and fibrinolytic cascade. (From Segen, Dictionary of Modern Medicine, 1992)
The relationship between the dose of an administered drug and the response of the organism to the drug.
Delivery of drugs into an artery.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Bleeding or escape of blood from a vessel.
Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein.
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Surgical removal of an obstructing clot or foreign material from a blood vessel at the point of its formation. Removal of a clot arising from a distant site is called EMBOLECTOMY.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V.
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Therapy with two or more separate preparations given for a combined effect.
A cell surface glycoprotein of endothelial cells that binds thrombin and serves as a cofactor in the activation of protein C and its regulation of blood coagulation.
A non-invasive technique using ultrasound for the measurement of cerebrovascular hemodynamics, particularly cerebral blood flow velocity and cerebral collateral flow. With a high-intensity, low-frequency pulse probe, the intracranial arteries may be studied transtemporally, transorbitally, or from below the foramen magnum.
Established cell cultures that have the potential to propagate indefinitely.
Retraction of a clot resulting from contraction of PLATELET pseudopods attached to FIBRIN strands. The retraction is dependent on the contractile protein thrombosthenin. Clot retraction is used as a measure of platelet function.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.
A LDL-receptor related protein involved in clearance of chylomicron remnants and of activated ALPHA-MACROGLOBULINS from plasma.
Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.
Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Agents that prevent clotting.
Radiography of the vascular system of the brain after injection of a contrast medium.
Pipecolic acids are cyclic amino acids, specifically a derivative of L-lysine, that can function as an indicator of certain metabolic disorders such as lysinuric protein intolerance and maple syrup urine disease.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
Physiologically inactive substances that can be converted to active enzymes.
The arterial blood vessels supplying the CEREBRUM.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The largest of the cerebral arteries. It trifurcates into temporal, frontal, and parietal branches supplying blood to most of the parenchyma of these lobes in the CEREBRAL CORTEX. These are the areas involved in motor, sensory, and speech activities.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Institutions with permanent facilities and organized medical staff which provide the full range of hospital services primarily to a neighborhood area.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Part of the arm in humans and primates extending from the ELBOW to the WRIST.
A grouping of three closely linked conditions: iris nevus (or Cogan-Reese) syndrome, Chandler Syndrome, and essential (progressive) iris atrophy. The most common features of this syndrome are the movement of endothelial cells off the cornea onto the iris leading to corneal swelling, distortion of the iris, and variable degrees of distortion of the pupil. The abnormal cell movement plugs fluid outflow channels of the eye causing GLAUCOMA.
Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Surgical removal of an obstructing clot or foreign material which has been transported from a distant vessel by the bloodstream. Removal of a clot at its original site is called THROMBECTOMY.
Inflammation of a vein associated with a blood clot (THROMBUS).
Laboratory tests for evaluating the individual's clotting mechanism.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Conveying ill or injured individuals from one place to another.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
A layer of epithelium that lines the heart, blood vessels (ENDOTHELIUM, VASCULAR), lymph vessels (ENDOTHELIUM, LYMPHATIC), and the serous cavities of the body.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The administration of substances into the eye with a hypodermic syringe.
The sum of the weight of all the atoms in a molecule.
Double-layered inflatable suits which, when inflated, exert pressure on the lower part of the wearer's body. The suits are used to improve or stabilize the circulatory state, i.e., to prevent hypotension, control hemorrhage, and regulate blood pressure. The suits are also used by pilots under positive acceleration.
A partial or complete return to the normal or proper physiologic activity of an organ or part following disease or trauma.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
Microsurgical revascularization to improve intracranial circulation. It usually involves joining the extracranial circulation to the intracranial circulation but may include extracranial revascularization (e.g., subclavian-vertebral artery bypass, subclavian-external carotid artery bypass). It is performed by joining two arteries (direct anastomosis or use of graft) or by free autologous transplantation of highly vascularized tissue to the surface of the brain.
Delivery of substances through VENIPUNCTURE into the VEINS.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
A secreted endopeptidase homologous with INTERSTITIAL COLLAGENASE, but which possesses an additional fibronectin-like domain.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36.
The circulation of blood through the BLOOD VESSELS of the BRAIN.
The formation or presence of a blood clot (THROMBUS) within a vein.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
An essential amino acid. It is often added to animal feed.
An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
The degree to which BLOOD VESSELS are not blocked or obstructed.
Services specifically designed, staffed, and equipped for the emergency care of patients.
Non-invasive method of vascular imaging and determination of internal anatomy without injection of contrast media or radiation exposure. The technique is used especially in CEREBRAL ANGIOGRAPHY as well as for studies of other vascular structures.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
Pathological processes consisting of the union of the opposing surfaces of a wound.
ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism.
A diagnostic technique that incorporates the measurement of molecular diffusion (such as water or metabolites) for tissue assessment by MRI. The degree of molecular movement can be measured by changes of apparent diffusion coefficient (ADC) with time, as reflected by tissue microstructure. Diffusion MRI has been used to study BRAIN ISCHEMIA and tumor response to treatment.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
The artery formed by the union of the right and left vertebral arteries; it runs from the lower to the upper border of the pons, where it bifurcates into the two posterior cerebral arteries.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Antibodies produced by a single clone of cells.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.
Amino derivatives of caproic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the amino caproic acid structure.
Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY.
The vein accompanying the femoral artery in the same sheath; it is a continuation of the popliteal vein and becomes the external iliac vein.
A way of providing emergency medical care that is guided by a thoughtful integration of the best available scientific knowledge with clinical expertise in EMERGENCY MEDICINE. This approach allows the practitioner to critically assess research data, clinical guidelines, and other information resources in order to correctly identify the clinical problem, apply the most high-quality intervention, and re-evaluate the outcome for future improvement.
A family of zinc-dependent metalloendopeptidases that is involved in the degradation of EXTRACELLULAR MATRIX components.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.

Optimal thrombolytic strategies for acute myocardial infarction--bolus administration. (1/3220)

Optimal strategies for thrombolysis in myocardial infarction (TIMI) are still being sought because the TIMI 3 flow rates achievable using standard regimens average approximately 60%. Double bolus administration of recombinant tissue plasminogen activator (tPA) is a novel approach with potential for earlier patency combined with ease of administration. We reviewed total patency rates, TIMI 3 patency rates, mortality, stroke and intracranial haemorrhage rates in the major trials of accelerated infusion tPA/bolus tPA/reteplase in acute myocardial infarction. A direct comparison was performed with results of two recent trials of double bolus (two 50 mg boli, 30 min apart) vs. accelerated infusion tPA: the Double Bolus Lytic Efficacy Trial (DBLE), an angiographic study, and the COBALT Trial, a mortality study. The DBLE trial showed equivalent patency rates for accelerated infusion and double bolus administration of tPA. Reviewing other angiographic trials, total patency and TIMI 3 patency rates achievable with double bolus tPA were comparable to those with accelerated infusion tPA or bolus reteplase administration. The COBALT study demonstrated a 30-day mortality of 7.53% in patients treated with accelerated infusion tPA compared with 7.98% for double bolus tPA treated patients. The small excess in mortality with double bolus treatment was confined to the elderly; in those < or = 75 years, mortality rates were 5.6% and 5.7%, for double bolus and accelerated infusion, respectively, and rates for death or non-fatal stroke were 6.35% and 6.3%, respectively. Comparison with other trials demonstrated mortality, stroke and intracranial haemorrhage rates with double bolus treatment similar to those associated with either accelerated infusion tPA or bolus reteplase treatment. Double bolus administration of tPA to patients with acute myocardial infarction is associated with total patency, TIMI 3 patency, mortality, stroke and intracranial haemorrhage rates similar to those associated with either accelerated infusion of tPA or bolus reteplase.  (+info)

Arterial flow conditions downregulate thrombomodulin on saphenous vein endothelium. (2/3220)

BACKGROUND: The antithrombogenic properties of venous endothelium may be attenuated when vein is implanted in the arterial circulation. Such changes may facilitate thrombosis, which is the final common pathway for saphenous vein arterial bypass graft occlusion. METHODS AND RESULTS: Using human saphenous vein in a validated ex vivo flow circuit, we investigated (1) the possibility that arterial flow conditions (mean pressure, 100 mm Hg, 90 cpm, approximately 200 mL/min) alter the concentration of proteins involved in regulating thrombosis at the vessel wall and (2) the influence of ion channel blockade on such effects. Concentrations of thrombomodulin and tissue factor were quantified by Western blotting (ratio of von Willebrand factor staining) and immunohistochemistry (as a percentage of CD31-staining area). Thrombomodulin concentrations after 90 minutes of venous and arterial flow conditions were quantified by immunostaining (68.9+/-4.8% and 41.0+/-3.0% CD31, respectively; P<0.01) and by Western blotting (1.35+/-0.20 and 0. 15+/-0.03 ratio of von Willebrand factor, respectively; P<0.01). The ability of endothelial cells to generate activated protein C also decreased from 62+/-14 to 19+/-10 ng. min-1. 1000 cells-1 (P=0.01). The significant reduction in thrombomodulin was attenuated if calcium was removed from the perfusate but not by external vein stenting. Inclusion in the vein perfusate of drugs that reduce calcium entry (including Gd3+, to block stretch-activated ion channels, and nifedipine) abolished the reduction in thrombomodulin concentration observed after arterial flow conditions. In freshly excised vein, negligible concentrations of tissue factor were detected on the endothelium and concentrations did not increase after 90 minutes of arterial flow conditions, although the inclusion of nifedipine caused the immunostaining to increase from 3.0+/-0.4% to 8.5+/-0.7% CD31 (P<0.02). CONCLUSIONS: In saphenous vein endothelium exposed to arterial flow conditions, there is rapid downregulation of thrombomodulin, sufficient to limit protein C activation, by a calcium-dependent mechanism.  (+info)

Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases. (3/3220)

Archetypal members of the chymotrypsin family of serine proteases, such as trypsin, chymotrypsin, and elastase, exhibit relatively broad substrate specificity. However, the successful development of efficient proteolytic cascades, such as the blood coagulation and fibrinolytic systems, required the evolution of proteases that displayed restricted specificity. Tissue-type plasminogen activator (t-PA), for example, possesses exquisitely stringent substrate specificity, and the molecular basis of this important biochemical property of t-PA remains obscure. Previous investigations of related serine proteases, which participate in the blood coagulation cascade, have focused attention on the residue that occupies position 192 (chymotrypsin numbering system), which plays a pivotal role in determining both the inhibitor and substrate specificity of these enzymes. Consequently, we created and characterized the kinetic properties of new variants of t-PA that contained point mutations at position 192. These studies demonstrated that, unlike in coagulation serine proteases, Gln-192 does not contribute significantly to the substrate or inhibitor specificity of t-PA in physiologically relevant reactions. Replacement of Gln-192 with a glutamic acid residue did, however, decrease the catalytic efficiency of mature, two-chain t-PA toward plasminogen in the absence of a fibrin co-factor.  (+info)

Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin. (4/3220)

BACKGROUND AND PURPOSE: We chose to evaluate the safety and efficacy of combined intrathrombus rtPA and intravenous heparin in cerebral venous thrombosis (CVT). METHODS: We treated 12 patients with symptoms of 1 to 40 days' duration (eg, headache, somnolence, focal deficits, seizures, and nausea and vomiting). Pretreatment MRI disclosed subtle hemorrhagic venous infarction in 4 patients, obvious hemorrhagic infarction in 2, small parenchymal hemorrhage from recent pallidotomy in 1, and no focal lesion in 5. Magnetic resonance venography and contrast venography identified thrombi in the superior sagittal sinus (SSS) in 3 patients; transverse/sigmoid sinus (TS/SS) in 2; SSS and both TS/SS in 1; SSS and 1 TS/SS in 5; and SSS, 1 TS/SS, and straight sinus in 1 patient. A loading dose of rtPA was instilled throughout the clot at 1 mg/cm, followed by continuous intrathrombus infusion at 1 to 2 mg/h. Intravenous heparin was infused concomitantly. RESULTS: Flow was restored completely in 6 patients and partially in 3, with a mean rtPA dose of 46 mg (range, 23 to 128 mg) at a mean time of 29 hours (range, 13 to 77 hours). Symptoms improved in these 9 patients concomitantly with flow restoration. Flow could not be restored in 3 patients. In 1 of them, treatment was stopped when little progress had been made, and fibrinogen level dropped to 118 mg/dL. In the other 2 patients, hemorrhagic worsening occurred, and treatment was abbreviated after initial rtPA dosing. In 1 of these, the hematoma was evacuated. CONCLUSIONS: Our experience with intrathrombus rtPA in conjunction with intravenous heparin in patients with CVT is encouraging. This therapy should probably be regarded as unsafe in patients with obvious hemorrhage. Time to restore flow may be faster than with urokinase (an average of 71 hours has been reported for 29 documented patients). Further evaluation of rtPA with heparin in CVT is warranted.  (+info)

Delayed increase in infarct volume after cerebral ischemia: correlations with thrombolytic treatment and clinical outcome. (5/3220)

BACKGROUND AND PURPOSE: Growing experimental evidence indicates that the development of cerebral ischemic damage is slower than previously believed. The aims of this work were (1) to study the evolution of CT hypoattenuation between 24 to 36 hours and 7 days in ischemic stroke patients; (2) to evaluate whether thrombolytic treatment given within 6 hours of stroke affects delayed infarction evolution; and (3) to investigate possible correlations between lesion volume changes over time and clinical outcome. METHODS: Of 620 patients included in the European Cooperative Acute Stroke Study 1 (ECASS1), we selected 450 patients whose control CT scans at day 1 (CT1) and day 7 (CT7) were available. They had been randomly divided into 2 groups: 206 patients had been treated with rtPA and 244 with placebo. CT1 and CT7 were classified according to the location of the infarct. The volume of CT hypoattenuation was measured using the formula AxBxC/2 for irregular volumes. The 95% confidence interval of inter- and intrarater variability was used to determine whether significant changes in lesion volume had occurred between CT1 and CT7. Clinical severity was evaluated by means of the Scandinavian Stroke Scale (SSS) at entry (SSS0) and at day 30 (SSS30). RESULTS: Mean lesion volumes were significantly (P<0.0001) higher at day 7 than at day 1 in all the subgroups of patients and particularly in patients with a subcortical lesion. Of the 450 patients studied, 287 (64%) did not show any significant change in lesion volume between CT1 and CT7, 143 (32%) showed a significant increase and the remaining 20 (4%) a significant decrease. No significant correlation was observed between treatment and lesion evolution between CT1 and CT7. Both clinical scores (SSS0 and SSS30) and degree of neurological recovery were significantly (P<0.05) lower in the subgroup of patients with a significant lesion volume increase than in the other 2 groups. CONCLUSIONS: In approximately two thirds of patients, infarct size is established 24 to 36 hours after stroke onset, whereas in the remaining one third, changes in lesion volume may occur later than the first 24 to 36 hours. Many factors may be responsible for delayed infarct enlargement and for a lower degree of clinical recovery, both of which may occur despite early recombinant tissue plasminogen activator treatment.  (+info)

Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. (6/3220)

BACKGROUND AND PURPOSE: We tested the hypothesis that treatment of embolic stroke with recombinant human tissue plasminogen activator (rhtPA) alters cerebral expression of adhesion molecules. METHODS: Male Wistar rats were subjected to middle cerebral artery occlusion by a single fibrin-rich clot. P-selectin, E-selectin, and intercellular adhesion molecule-1 (ICAM-1) immunoreactivity was measured at 6 or 24 hours after embolic stroke in control rats and in rats treated with rhtPA at 1 or 4 hours after stroke. To examine the therapeutic efficacy of combined rhtPA and anti-ICAM-1 antibody treatment at 4 hours after embolization, ischemic lesion volumes were measured in rats treated with rhtPA alone, rats treated with rhtPA and anti-ICAM-1 antibody, and nontreated rats. RESULTS: Administration of rhtPA at 1 hour after embolization resulted in a significant reduction of adhesion molecule vascular immunoreactivity after embolization in the ipsilateral hemisphere compared with corresponding control rats. However, when rhtPA was administered to rats at 4 hours after embolization, significant increases of adhesion molecule immunoreactivity in the ipsilateral hemisphere were detected. A significant increase of ICAM-1 immunoreactivity was also detected in the contralateral hemisphere at 24 hours after ischemia. A significant reduction in lesion volume was found in rats treated with the combination of rhtPA and anti-ICAM-1 antibody compared with rats treated only with rhtPA. CONCLUSIONS: The present study suggests that the time of initiation of thrombolytic therapy alters vascular immunoreactivity of inflammatory adhesion molecules in the ischemic brain and that therapeutic benefit can be obtained by combining rhtPA and anti-ICAM-1 antibody treatment 4 hours after stroke.  (+info)

Intra-arterial rtPA treatment of stroke assessed by diffusion- and perfusion-weighted MRI. (7/3220)

BACKGROUND: Diffusion-weighted MRI (DWI) and perfusion-weighted MRI (PWI) are new techniques that can be used for the evaluation of acute ischemic stroke. However, their potential role in the management of patients treated with recombinant tissue plasminogen activator (rtPA) has yet to be determined. CASE DESCRIPTION: The authors present the case of a 73-year-old man who was treated with intra-arterial rtPA, and they compare findings on DWI and PWI scans with angiography. PWI revealed decreased cerebral perfusion corresponding to an area that was not successfully recanalized, but revealed no abnormality in regions in which blood flow was restored. DWI was unremarkable in the region that was reperfused early (3 hours) but revealed hyperintensity in an area that was reperfused 3. 5 hours after symptom onset and in the area that was not reperfused. CONCLUSIONS: Findings on PWI correlated well with angiography, and DWI detected injured tissue in the hyperacute stage, whereas conventional MRI findings were negative. This suggests that these techniques may be useful to noninvasively evaluate the success of thrombolytic therapy.  (+info)

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. (8/3220)

BACKGROUND: We investigated whether administration of a soluble recombinant P-selectin glycoprotein ligand-1 chimera (rPSGL-Ig) in conjunction with thrombolytic therapy would enhance thrombolysis by preventing ongoing interactions of leukocytes with platelets and the injured arterial wall. METHODS AND RESULTS: An occlusive thrombus was formed in an internal iliac artery of Yorkshire pigs by placement of a copper coil in the artery under fluoroscopic guidance. Pigs then received heparin and, 15 minutes later, either vehicle or rPSGL-Ig followed by infusion with 25 mg tissue plasminogen activator according to the 90-minute regimen. Blood flow through the artery was monitored by angiography and scored on a scale of 0 to 3. Lysis of the thrombus was accelerated by 70% in pigs treated with rPSGL-Ig 250 microg/kg compared with control (13.3+/-5.0 versus 44. 4+/-13.3 minutes; n=9 each). Eight of 9 control pigs reoccluded in 13.8+/-16.9 minutes after the end of tissue plasminogen activator infusion, whereas no reocclusion was observed in 8 of 9 pigs in the rPSGL-Ig group. When the dose of rPSGL-Ig was increased to 500 microg/kg, time to lysis was shortened by 61% from control (18.0+/-8. 4 versus 46.0+/-8.9 minutes). Reocclusion occurred in 6.0+/-15.2 minutes in control but not in any rPSGL-Ig-treated pig (n=5 each). In addition, near-normal flow (score 2 or 3) after thrombolysis was achieved 59% and 58% faster in the 2 rPSGL-Ig groups than in their respective controls. CONCLUSIONS: Inhibition of leukocyte accumulation at the site of thrombosis with rPSGL-Ig may represent a safe therapeutic intervention that could be important in accelerating thrombolysis, achieving optimal reperfusion, and reducing incidence of acute reocclusion.  (+info)

Tissue Plasminogen Activator (tPA) is a thrombolytic enzyme, which means it dissolves blood clots. It is naturally produced by the endothelial cells that line the interior surface of blood vessels. tPA activates plasminogen, a zymogen, to convert it into plasmin, a protease that breaks down fibrin, the structural protein in blood clots. This enzyme is used medically as a thrombolytic drug under various brand names, such as Activase and Alteplase, to treat conditions like acute ischemic stroke, pulmonary embolism, and deep vein thrombosis by dissolving the clots and restoring blood flow.

Plasminogen Activator Inhibitor 1 (PAI-1) is a protein involved in the regulation of fibrinolysis, which is the body's natural process of breaking down blood clots. PAI-1 inhibits tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), two enzymes that convert plasminogen to plasmin, which degrades fibrin clots. Therefore, PAI-1 acts as a natural antagonist of the fibrinolytic system, promoting clot formation and stability. Increased levels of PAI-1 have been associated with thrombotic disorders, such as deep vein thrombosis and pulmonary embolism.

Urokinase-type plasminogen activator (uPA) is a serine protease enzyme that plays a crucial role in the degradation of the extracellular matrix and cell migration. It catalyzes the conversion of plasminogen to plasmin, which then breaks down various proteins in the extracellular matrix, leading to tissue remodeling and repair.

uPA is synthesized as a single-chain molecule, pro-uPA, which is activated by cleavage into two chains, forming the mature and active enzyme. uPA binds to its specific receptor, uPAR, on the cell surface, where it exerts its proteolytic activity.

Abnormal regulation of uPA and uPAR has been implicated in various pathological conditions, including cancer, where they contribute to tumor invasion and metastasis. Therefore, uPA is a potential target for therapeutic intervention in cancer and other diseases associated with excessive extracellular matrix degradation.

Plasminogen activators are a group of enzymes that play a crucial role in the body's fibrinolytic system, which is responsible for breaking down and removing blood clots. These enzymes activate plasminogen, a zymogen (inactive precursor) found in circulation, converting it into plasmin - a protease that degrades fibrin, the insoluble protein mesh that forms the structural basis of a blood clot.

There are two main types of plasminogen activators:

1. Tissue Plasminogen Activator (tPA): This is a serine protease primarily produced by endothelial cells lining blood vessels. tPA has a higher affinity for fibrin-bound plasminogen and is therefore more specific in activating plasmin at the site of a clot, helping to localize fibrinolysis and minimize bleeding risks.
2. Urokinase Plasminogen Activator (uPA): This is another serine protease found in various tissues and body fluids, including urine. uPA can be produced by different cell types, such as macrophages and fibroblasts. Unlike tPA, uPA does not have a strong preference for fibrin-bound plasminogen and can activate plasminogen in a more general manner, which might contribute to its role in processes like tissue remodeling and cancer progression.

Plasminogen activators are essential for maintaining vascular homeostasis by ensuring the proper removal of blood clots and preventing excessive fibrin accumulation. They have also been implicated in various pathological conditions, including thrombosis, hemorrhage, and tumor metastasis.

Plasminogen is a glycoprotein that is present in human plasma, and it is the inactive precursor of the enzyme plasmin. Plasmin is a serine protease that plays a crucial role in the dissolution of blood clots by degrading fibrin, one of the major components of a blood clot.

Plasminogen can be activated to form plasmin through the action of various activators, such as tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Once activated, plasmin can break down fibrin and other proteins, helping to prevent excessive clotting and promoting the normal turnover of extracellular matrix components.

Abnormalities in plasminogen activation have been implicated in various diseases, including thrombosis, fibrosis, and cancer. Therefore, understanding the regulation and function of plasminogen is important for developing therapies to treat these conditions.

Fibrinolysis is the natural process in the body that leads to the dissolution of blood clots. It is a vital part of hemostasis, the process that regulates bleeding and wound healing. Fibrinolysis occurs when plasminogen activators convert plasminogen to plasmin, an enzyme that breaks down fibrin, the insoluble protein mesh that forms the structure of a blood clot. This process helps to prevent excessive clotting and maintains the fluidity of the blood. In medical settings, fibrinolysis can also refer to the therapeutic use of drugs that stimulate this process to dissolve unwanted or harmful blood clots, such as those that cause deep vein thrombosis or pulmonary embolism.

Fibrinolytic agents are medications that dissolve or break down blood clots by activating plasminogen, which is converted into plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the structural protein in blood clots. Fibrinolytic agents are used medically to treat conditions such as acute ischemic stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction (heart attack) by restoring blood flow in occluded vessels. Examples of fibrinolytic agents include alteplase, reteplase, and tenecteplase. It is important to note that these medications carry a risk of bleeding complications and should be administered with caution.

Plasminogen inactivators are substances that inhibit the activity of plasminogen, a proenzyme that is converted into the active enzyme plasmin. Plasmin plays a crucial role in the breakdown of blood clots by cleaving fibrin, the protein that forms the structural framework of a clot.

There are two main types of plasminogen activators: tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). These enzymes convert plasminogen into plasmin, thereby promoting fibrinolysis, or the dissolution of blood clots. Plasminogen inactivators, on the other hand, inhibit this process by blocking the conversion of plasminogen to plasmin.

Plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) are two main types of plasminogen inactivators. PAI-1 is a serine protease inhibitor that inactivates tPA and uPA by forming covalent complexes with them. PAI-1 is produced by various cells, including endothelial cells, hepatocytes, and adipocytes. Elevated levels of PAI-1 have been associated with an increased risk of thrombosis and cardiovascular disease.

PAI-2 is another serine protease inhibitor that primarily inhibits uPA. It is produced by various cells, including monocytes, macrophages, and trophoblasts. PAI-2 has been shown to play a role in pregnancy, immune response, and cancer.

Overall, plasminogen inactivators are important regulators of the fibrinolytic system, which helps maintain blood flow and prevent excessive clotting or bleeding. Dysregulation of this system can lead to various pathological conditions, such as thrombosis, hemorrhage, and cancer.

Fibrinolysin is defined as a proteolytic enzyme that dissolves or breaks down fibrin, a protein involved in the clotting of blood. This enzyme is produced by certain cells, such as endothelial cells that line the interior surface of blood vessels, and is an important component of the body's natural mechanism for preventing excessive blood clotting and maintaining blood flow.

Fibrinolysin works by cleaving specific bonds in the fibrin molecule, converting it into soluble degradation products that can be safely removed from the body. This process is known as fibrinolysis, and it helps to maintain the balance between clotting and bleeding in the body.

In medical contexts, fibrinolysin may be used as a therapeutic agent to dissolve blood clots that have formed in the blood vessels, such as those that can occur in deep vein thrombosis or pulmonary embolism. It is often administered in combination with other medications that help to enhance its activity and specificity for fibrin.

Urokinase Plasminogen Activator Receptors (uPAR) are a type of cell surface receptor that play a role in several biological processes including cell migration, tissue remodeling, and angiogenesis. They bind to urokinase plasminogen activator (uPA), a serine protease that converts plasminogen to plasmin, leading to the degradation of extracellular matrix components.

The interaction between uPAR and uPA plays a crucial role in various physiological processes such as wound healing and tissue repair, but it has also been implicated in several pathological conditions, including cancer, where it contributes to tumor cell invasion and metastasis. The regulation of uPAR expression and activity is therefore an important area of research for the development of new therapeutic strategies.

Thrombolytic therapy, also known as thrombolysis, is a medical treatment that uses medications called thrombolytics or fibrinolytics to dissolve or break down blood clots (thrombi) in blood vessels. These clots can obstruct the flow of blood to vital organs such as the heart, lungs, or brain, leading to serious conditions like myocardial infarction (heart attack), pulmonary embolism, or ischemic stroke.

The goal of thrombolytic therapy is to restore blood flow as quickly and efficiently as possible to prevent further damage to the affected organ and potentially save lives. Commonly used thrombolytic drugs include alteplase (tPA), reteplase, and tenecteplase. It's essential to administer these medications as soon as possible after the onset of symptoms for optimal treatment outcomes. However, there are risks associated with thrombolytic therapy, such as an increased chance of bleeding complications, which must be carefully weighed against its benefits in each individual case.

Fibrin is defined as a protein that is formed from fibrinogen during the clotting of blood. It plays an essential role in the formation of blood clots, also known as a clotting or coagulation cascade. When an injury occurs and bleeding starts, fibrin threads form a net-like structure that entraps platelets and red blood cells to create a stable clot, preventing further loss of blood.

The process of forming fibrin from fibrinogen is initiated by thrombin, another protein involved in the coagulation cascade. Thrombin cleaves fibrinogen into fibrin monomers, which then polymerize to form long strands of fibrin. These strands cross-link with each other through a process catalyzed by factor XIIIa, forming a stable clot that protects the wound and promotes healing.

It is important to note that abnormalities in fibrin formation or breakdown can lead to bleeding disorders or thrombotic conditions, respectively. Proper regulation of fibrin production and degradation is crucial for maintaining healthy hemostasis and preventing excessive clotting or bleeding.

A stroke, also known as cerebrovascular accident (CVA), is a serious medical condition that occurs when the blood supply to part of the brain is interrupted or reduced, leading to deprivation of oxygen and nutrients to brain cells. This can result in the death of brain tissue and cause permanent damage or temporary impairment to cognitive functions, speech, memory, movement, and other body functions controlled by the affected area of the brain.

Strokes can be caused by either a blockage in an artery that supplies blood to the brain (ischemic stroke) or the rupture of a blood vessel in the brain (hemorrhagic stroke). A transient ischemic attack (TIA), also known as a "mini-stroke," is a temporary disruption of blood flow to the brain that lasts only a few minutes and does not cause permanent damage.

Symptoms of a stroke may include sudden weakness or numbness in the face, arm, or leg; difficulty speaking or understanding speech; vision problems; loss of balance or coordination; severe headache with no known cause; and confusion or disorientation. Immediate medical attention is crucial for stroke patients to receive appropriate treatment and prevent long-term complications.

Plasminogen Activator Inhibitor 2 (PAI-2) is a protein involved in the regulation of fibrinolysis, which is the body's natural process of breaking down blood clots. PAI-2 is a specific inhibitor of two enzymes called tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), which play a crucial role in the activation of plasminogen to plasmin, an enzyme that degrades fibrin clots.

PAI-2 is primarily produced by cells in the immune system, such as monocytes and macrophages, but it can also be found in other tissues, including the placenta during pregnancy. The main function of PAI-2 is to control and limit the activity of tPA and uPA, thereby preventing excessive fibrinolysis and maintaining a balance between clot formation and dissolution.

In certain pathological conditions, such as sepsis or cancer, PAI-2 levels can be elevated, leading to an impaired fibrinolytic system and contributing to the development of thrombosis (blood clots) and organ dysfunction.

Streptokinase is a thrombolytic or clot-busting enzyme produced by certain strains of streptococcus bacteria. It functions by converting plasminogen to plasmin, which then degrades fibrin, a protein that forms the structural framework of blood clots. This activity helps in dissolving blood clots and restoring blood flow in areas obstructed by them. In a medical context, streptokinase is often used as a medication to treat conditions associated with abnormal blood clotting, such as heart attacks, pulmonary embolisms, and deep vein thromboses. However, its use carries the risk of bleeding complications due to excessive fibrinolysis or clot dissolution.

Brain ischemia is the medical term used to describe a reduction or interruption of blood flow to the brain, leading to a lack of oxygen and glucose delivery to brain tissue. This can result in brain damage or death of brain cells, known as infarction. Brain ischemia can be caused by various conditions such as thrombosis (blood clot formation), embolism (obstruction of a blood vessel by a foreign material), or hypoperfusion (reduced blood flow). The severity and duration of the ischemia determine the extent of brain damage. Symptoms can range from mild, such as transient ischemic attacks (TIAs or "mini-strokes"), to severe, including paralysis, speech difficulties, loss of consciousness, and even death. Immediate medical attention is required for proper diagnosis and treatment to prevent further damage and potential long-term complications.

A cerebral hemorrhage, also known as an intracranial hemorrhage or intracerebral hemorrhage, is a type of stroke that results from bleeding within the brain tissue. It occurs when a weakened blood vessel bursts and causes localized bleeding in the brain. This bleeding can increase pressure in the skull, damage nearby brain cells, and release toxic substances that further harm brain tissues.

Cerebral hemorrhages are often caused by chronic conditions like hypertension (high blood pressure) or cerebral amyloid angiopathy, which weakens the walls of blood vessels over time. Other potential causes include trauma, aneurysms, arteriovenous malformations, illicit drug use, and brain tumors. Symptoms may include sudden headache, weakness, numbness, difficulty speaking or understanding speech, vision problems, loss of balance, and altered level of consciousness. Immediate medical attention is required to diagnose and manage cerebral hemorrhage through imaging techniques, supportive care, and possible surgical interventions.

Alpha-2-antiplasmin (α2AP) is a protein found in the blood plasma that inhibits fibrinolysis, the process by which blood clots are broken down. It does this by irreversibly binding to and inhibiting plasmin, an enzyme that degrades fibrin clots.

Alpha-2-antiplasmin is one of the most important regulators of fibrinolysis, helping to maintain a balance between clot formation and breakdown. Deficiencies or dysfunction in alpha-2-antiplasmin can lead to an increased risk of bleeding due to uncontrolled plasmin activity.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Annexin A2 is a protein found in various types of cells, including those that line the inside of blood vessels. It is a member of the annexin family of proteins, which are characterized by their ability to bind to calcium ions and membranes. Annexin A2 is involved in several cellular processes, including the regulation of ion channels, the modulation of enzyme activity, and the promotion of cell adhesion and migration. It also plays a role in the coagulation of blood, and has been implicated in the development and progression of various diseases, including cancer and cardiovascular disease.

Intracranial thrombosis refers to the formation of a blood clot (thrombus) within the intracranial vessels, which supply blood to the brain. This condition can occur in any of the cerebral arteries or veins and can lead to serious complications such as ischemic stroke, transient ischemic attack (TIA), or venous sinus thrombosis.

The formation of an intracranial thrombus can be caused by various factors, including atherosclerosis, cardiac embolism, vasculitis, sickle cell disease, hypercoagulable states, and head trauma. Symptoms may vary depending on the location and extent of the thrombosis but often include sudden onset of headache, weakness or numbness in the face or limbs, difficulty speaking or understanding speech, vision changes, and loss of balance or coordination.

Diagnosis of intracranial thrombosis typically involves imaging studies such as computed tomography (CT) angiography, magnetic resonance angiography (MRA), or digital subtraction angiography (DSA). Treatment options may include anticoagulation therapy, thrombolysis, endovascular intervention, or surgical intervention, depending on the underlying cause and severity of the condition.

Fibrinogen is a soluble protein present in plasma, synthesized by the liver. It plays an essential role in blood coagulation. When an injury occurs, fibrinogen gets converted into insoluble fibrin by the action of thrombin, forming a fibrin clot that helps to stop bleeding from the injured site. Therefore, fibrinogen is crucial for hemostasis, which is the process of stopping bleeding and starting the healing process after an injury.

Hemostasis is the physiological process that occurs to stop bleeding (bleeding control) when a blood vessel is damaged. This involves the interaction of platelets, vasoconstriction, and blood clotting factors leading to the formation of a clot. The ultimate goal of hemostasis is to maintain the integrity of the vascular system while preventing excessive blood loss.

Intravenous injections are a type of medical procedure where medication or fluids are administered directly into a vein using a needle and syringe. This route of administration is also known as an IV injection. The solution injected enters the patient's bloodstream immediately, allowing for rapid absorption and onset of action. Intravenous injections are commonly used to provide quick relief from symptoms, deliver medications that are not easily absorbed by other routes, or administer fluids and electrolytes in cases of dehydration or severe illness. It is important that intravenous injections are performed using aseptic technique to minimize the risk of infection.

Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a clot forms in an artery, it can cut off the supply of oxygen and nutrients to the tissues served by that artery, leading to damage or tissue death. If a thrombus forms in the heart, it can cause a heart attack. If a thrombus breaks off and travels through the bloodstream, it can lodge in a smaller vessel, causing blockage and potentially leading to damage in the organ that the vessel supplies. This is known as an embolism.

Thrombosis can occur due to various factors such as injury to the blood vessel wall, abnormalities in blood flow, or changes in the composition of the blood. Certain medical conditions, medications, and lifestyle factors can increase the risk of thrombosis. Treatment typically involves anticoagulant or thrombolytic therapy to dissolve or prevent further growth of the clot, as well as addressing any underlying causes.

Fibrin(ogen) degradation products (FDPs) are a group of proteins that result from the breakdown of fibrinogen and fibrin, which are key components of blood clots. This process occurs during the normal physiological process of fibrinolysis, where clots are dissolved to maintain blood flow.

FDPs can be measured in the blood as a marker for the activation of the coagulation and fibrinolytic systems. Elevated levels of FDPs may indicate the presence of a disorder that causes abnormal clotting or bleeding, such as disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of cancer.

It is important to note that FDPs are not specific to any particular disorder and their measurement should be interpreted in conjunction with other clinical and laboratory findings.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Middle Cerebral Artery (MCA) infarction is a type of ischemic stroke that occurs when there is an obstruction in the blood supply to the middle cerebral artery, which is one of the major blood vessels that supplies oxygenated blood to the brain. The MCA supplies blood to a large portion of the brain, including the motor and sensory cortex, parts of the temporal and parietal lobes, and the basal ganglia.

An infarction is the death of tissue due to the lack of blood supply, which can lead to damage or loss of function in the affected areas of the brain. Symptoms of MCA infarction may include weakness or numbness on one side of the body, difficulty speaking or understanding speech, vision problems, and altered levels of consciousness.

MCA infarctions can be caused by various factors, including embolism (a blood clot that travels to the brain from another part of the body), thrombosis (a blood clot that forms in the MCA itself), or stenosis (narrowing of the artery due to atherosclerosis or other conditions). Treatment for MCA infarction may include medications to dissolve blood clots, surgery to remove the obstruction, or rehabilitation to help regain lost function.

Intracranial hemorrhage (ICH) is a type of stroke caused by bleeding within the brain or its surrounding tissues. It's a serious medical emergency that requires immediate attention and treatment. The bleeding can occur in various locations:

1. Epidural hematoma: Bleeding between the dura mater (the outermost protective covering of the brain) and the skull. This is often caused by trauma, such as a head injury.
2. Subdural hematoma: Bleeding between the dura mater and the brain's surface, which can also be caused by trauma.
3. Subarachnoid hemorrhage: Bleeding in the subarachnoid space, which is filled with cerebrospinal fluid (CSF) and surrounds the brain. This type of ICH is commonly caused by the rupture of an intracranial aneurysm or arteriovenous malformation.
4. Intraparenchymal hemorrhage: Bleeding within the brain tissue itself, which can be caused by hypertension (high blood pressure), amyloid angiopathy, or trauma.
5. Intraventricular hemorrhage: Bleeding into the brain's ventricular system, which contains CSF and communicates with the subarachnoid space. This type of ICH is often seen in premature infants but can also be caused by head trauma or aneurysm rupture in adults.

Symptoms of intracranial hemorrhage may include sudden severe headache, vomiting, altered consciousness, confusion, seizures, weakness, numbness, or paralysis on one side of the body, vision changes, or difficulty speaking or understanding speech. Rapid diagnosis and treatment are crucial to prevent further brain damage and potential long-term disabilities or death.

Carboxypeptidase B is a type of enzyme that belongs to the peptidase family. It is also known as carboxypeptidase B1 or CpB. This enzyme plays a crucial role in the digestion of proteins by cleaving specific amino acids from the carboxyl-terminal end of polypeptides.

Carboxypeptidase B preferentially removes basic arginine and lysine residues from protein substrates, making it an essential enzyme in various physiological processes, including blood clotting, hormone processing, and neuropeptide metabolism. It is synthesized as an inactive zymogen, procarboxypeptidase B, which is converted to its active form upon proteolytic activation.

In addition to its physiological functions, carboxypeptidase B has applications in research and industry, such as protein sequencing, peptide synthesis, and food processing.

An intracranial embolism is a medical condition that occurs when a blood clot or other foreign material (embolus) forms elsewhere in the body and travels to the blood vessels within the brain. This embolus then blocks the flow of blood in the cerebral arteries, leading to potential damage or death of brain tissue. Common sources of intracranial emboli include heart conditions such as atrial fibrillation, valvular heart disease, or following a heart attack; or from large-vessel atherosclerosis in the carotid arteries. Symptoms can vary depending on the location and size of the obstruction, but may include sudden weakness or numbness, confusion, difficulty speaking, vision loss, severe headache, or even loss of consciousness. Immediate medical attention is required to diagnose and treat intracranial embolism, often involving anticoagulation therapy, endovascular procedures, or surgery.

Intravenous (IV) infusion is a medical procedure in which liquids, such as medications, nutrients, or fluids, are delivered directly into a patient's vein through a needle or a catheter. This route of administration allows for rapid absorption and distribution of the infused substance throughout the body. IV infusions can be used for various purposes, including resuscitation, hydration, nutrition support, medication delivery, and blood product transfusion. The rate and volume of the infusion are carefully controlled to ensure patient safety and efficacy of treatment.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Reperfusion, in medical terms, refers to the restoration of blood flow to tissues or organs that have been deprived of adequate oxygen supply, usually as a result of ischemia (lack of blood flow). This process is often initiated through therapeutic interventions such as thrombolysis (breaking up blood clots), angioplasty (opening narrowed or blocked blood vessels using a balloon or stent), or surgical procedures.

Reperfusion aims to salvage the affected tissues and prevent further damage; however, it can also lead to reperfusion injury. This injury occurs when the return of oxygen-rich blood to previously ischemic tissues results in the overproduction of free radicals and inflammatory mediators, which can cause additional cellular damage and organ dysfunction.

Managing reperfusion injury involves using various strategies such as antioxidants, anti-inflammatory agents, and other protective treatments to minimize its negative impact on the recovering tissues or organs.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Serpin E2, also known as Neuroserpin, is a member of the serine protease inhibitor (Serpin) superfamily. It is primarily expressed in neuronal cells and plays a crucial role in regulating tissue plasminogen activator (tPA), a protein involved in the breakdown of blood clots. Serpin E2 helps to prevent excessive proteolytic activity, which can lead to neurodegeneration and other neurological disorders. Mutations in the SERPINE2 gene have been associated with certain forms of dementia and cerebral amyloid angiopathy (CAA), a condition characterized by the accumulation of beta-amyloid protein in the walls of blood vessels in the brain.

A retinal hemorrhage is a type of bleeding that occurs in the blood vessels of the retina, which is the light-sensitive tissue located at the back of the eye. This condition can result from various underlying causes, including diabetes, high blood pressure, age-related macular degeneration, or trauma to the eye. Retinal hemorrhages can be categorized into different types based on their location and appearance, such as dot and blot hemorrhages, flame-shaped hemorrhages, or subhyaloid hemorrhages. Depending on the severity and cause of the hemorrhage, treatment options may vary from monitoring to laser therapy, medication, or even surgery. It is essential to consult an ophthalmologist for a proper evaluation and management plan if you suspect a retinal hemorrhage.

I'm sorry for any confusion, but "Isoflurophate" does not appear to be a recognized term in medical or scientific literature. It is possible that there may be a spelling error or typo in the term you are looking for. If you meant "Isoflurane," which is a commonly used anesthetic in medical and surgical procedures, I can provide a definition for that.

Isoflurane: A volatile halogenated ether liquid used as an inhalational general anesthetic agent. It has a rapid onset and offset of action, making it useful for both induction and maintenance of anesthesia. Isoflurane is also known to have bronchodilatory properties, which can be beneficial in patients with reactive airway disease or asthma.

Cell surface receptors, also known as membrane receptors, are proteins located on the cell membrane that bind to specific molecules outside the cell, known as ligands. These receptors play a crucial role in signal transduction, which is the process of converting an extracellular signal into an intracellular response.

Cell surface receptors can be classified into several categories based on their structure and mechanism of action, including:

1. Ion channel receptors: These receptors contain a pore that opens to allow ions to flow across the cell membrane when they bind to their ligands. This ion flux can directly activate or inhibit various cellular processes.
2. G protein-coupled receptors (GPCRs): These receptors consist of seven transmembrane domains and are associated with heterotrimeric G proteins that modulate intracellular signaling pathways upon ligand binding.
3. Enzyme-linked receptors: These receptors possess an intrinsic enzymatic activity or are linked to an enzyme, which becomes activated when the receptor binds to its ligand. This activation can lead to the initiation of various signaling cascades within the cell.
4. Receptor tyrosine kinases (RTKs): These receptors contain intracellular tyrosine kinase domains that become activated upon ligand binding, leading to the phosphorylation and activation of downstream signaling molecules.
5. Integrins: These receptors are transmembrane proteins that mediate cell-cell or cell-matrix interactions by binding to extracellular matrix proteins or counter-receptors on adjacent cells. They play essential roles in cell adhesion, migration, and survival.

Cell surface receptors are involved in various physiological processes, including neurotransmission, hormone signaling, immune response, and cell growth and differentiation. Dysregulation of these receptors can contribute to the development of numerous diseases, such as cancer, diabetes, and neurological disorders.

"Kringles" is not a term commonly used in medical literature. It is a term that originates from Scandinavian folklore, referring to a mythical figure who delivers gifts and sweets to children. However, in the context of biochemistry and cell biology, Kringle domains are structural motifs found in certain proteins.

Kringle domains are small, compact protein domains that contain approximately 80-100 amino acids, characterized by a distinctive pattern of disulfide bonds. These domains are named after the Danish pastry "kringle," which has a knot-like shape similar to the structure of these protein domains. Kringle domains are found in several proteins involved in blood coagulation, fibrinolysis, and inflammation, such as plasminogen, urokinase-type plasminogen activator (uPA), and tissue plasminogen activator (tPA). They play a role in protein-protein interactions, cell signaling, and protease activation.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

The endothelium is a thin layer of simple squamous epithelial cells that lines the interior surface of blood vessels, lymphatic vessels, and heart chambers. The vascular endothelium, specifically, refers to the endothelial cells that line the blood vessels. These cells play a crucial role in maintaining vascular homeostasis by regulating vasomotor tone, coagulation, platelet activation, inflammation, and permeability of the vessel wall. They also contribute to the growth and repair of the vascular system and are involved in various pathological processes such as atherosclerosis, hypertension, and diabetes.

The National Institute of Neurological Disorders and Stroke (NINDS) is not a medical term per se, but rather the name of a US government research institution. According to its official website, NINDS is one of the 27 Institutes and Centers that make up the National Institutes of Health (NIH), which is the primary federal agency responsible for conducting and supporting medical research in the United States.

NINDS's mission is to "seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease." It supports and conducts research on a wide range of neurological disorders, including Alzheimer's disease, stroke, epilepsy, Parkinson's disease, and many others. NINDS also provides information and resources for patients, families, and healthcare providers affected by these conditions.

Serine proteinase inhibitors, also known as serine protease inhibitors or serpins, are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins in a process called proteolysis. Serine proteinases are important in many biological processes such as blood coagulation, fibrinolysis, inflammation and cell death. The inhibition of these enzymes by serpin proteins is an essential regulatory mechanism to maintain the balance and prevent uncontrolled proteolytic activity that can lead to diseases.

Serpins work by forming a covalent complex with their target serine proteinases, irreversibly inactivating them. The active site of serpins contains a reactive center loop (RCL) that mimics the protease's target protein sequence and acts as a bait for the enzyme. When the protease cleaves the RCL, it gets trapped within the serpin structure, leading to its inactivation.

Serpin proteinase inhibitors play crucial roles in various physiological processes, including:

1. Blood coagulation and fibrinolysis regulation: Serpins such as antithrombin, heparin cofactor II, and protease nexin-2 control the activity of enzymes involved in blood clotting and dissolution to prevent excessive or insufficient clot formation.
2. Inflammation modulation: Serpins like α1-antitrypsin, α2-macroglobulin, and C1 inhibitor regulate the activity of proteases released during inflammation, protecting tissues from damage.
3. Cell death regulation: Some serpins, such as PI-9/SERPINB9, control apoptosis (programmed cell death) by inhibiting granzyme B, a protease involved in this process.
4. Embryonic development and tissue remodeling: Serpins like plasminogen activator inhibitor-1 (PAI-1) and PAI-2 regulate the activity of enzymes involved in extracellular matrix degradation during embryonic development and tissue remodeling.
5. Neuroprotection: Serpins such as neuroserpin protect neurons from damage by inhibiting proteases released during neuroinflammation or neurodegenerative diseases.

Dysregulation of serpins has been implicated in various pathological conditions, including thrombosis, emphysema, Alzheimer's disease, and cancer. Understanding the roles of serpins in these processes may provide insights into potential therapeutic strategies for treating these diseases.

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

Aminocaproic acid is an antifibrinolytic medication, which means it helps to prevent the breakdown of blood clots. It works by blocking plasmin, an enzyme in your body that dissolves blood clots.

This drug is used for the treatment of bleeding conditions due to various causes, such as:

1. Excessive menstrual bleeding (menorrhagia)
2. Bleeding after tooth extraction or surgery
3. Hematuria (blood in urine) due to certain medical procedures or conditions like kidney stones
4. Intracranial hemorrhage (bleeding inside the skull)
5. Hereditary angioedema, a genetic disorder that causes swelling of various parts of the body

Aminocaproic acid is available in oral and injectable forms. Common side effects include nausea, vomiting, diarrhea, and headache. Serious side effects are rare but may include allergic reactions, seizures, or vision changes. It's essential to use this medication under the supervision of a healthcare professional, as improper usage might lead to blood clots, stroke, or other severe complications.

1. Intracranial Embolism: This is a medical condition that occurs when a blood clot or other particle (embolus) formed elsewhere in the body, travels through the bloodstream and lodges itself in the intracranial blood vessels, blocking the flow of blood to a part of the brain. This can lead to various neurological symptoms such as weakness, numbness, speech difficulties, or even loss of consciousness, depending on the severity and location of the blockage.

2. Intracranial Thrombosis: This is a medical condition that occurs when a blood clot (thrombus) forms within the intracranial blood vessels. The clot can partially or completely obstruct the flow of blood, leading to various symptoms such as headache, confusion, seizures, or neurological deficits, depending on the severity and location of the thrombosis. Intracranial thrombosis can occur due to various factors including atherosclerosis, hypertension, diabetes, and other medical conditions that increase the risk of blood clot formation.

Ultrasonic therapy, also known as therapeutic ultrasound, is a treatment method used in physical therapy and rehabilitation that utilizes sound waves with frequencies higher than the upper limit of human hearing. In most cases, the frequency ranges from 800,000 to 2,000,000 Hz (cycles per second).

During ultrasonic therapy, a small device called a transducer is placed in direct contact with the patient's skin. The transducer emits ultrasonic waves that are primarily absorbed by soft tissues directly beneath the skin's surface, including muscles, tendons, and ligaments. These sound waves cause microscopic vibrations in the tissue molecules, which can produce various therapeutic effects:

1. Deep heating: The vibration of tissue molecules generates heat within the treated area, increasing local blood flow, reducing muscle tension, and promoting healing. This effect is particularly beneficial for treating chronic pain, muscle spasms, joint stiffness, and soft tissue injuries.
2. Cavitation: High-intensity ultrasonic waves can create tiny gas bubbles in the fluid surrounding the tissue cells. When these bubbles collapse (a process called cavitation), they generate intense localized pressure that may help break down scar tissue, reduce adhesions, and improve tissue mobility.
3. Non-thermal effects: Low-intensity ultrasonic waves can stimulate cellular processes without causing significant heating. These non-thermal effects include enhanced metabolism, increased collagen production, and improved nutrient exchange in the treated tissues, which may contribute to faster healing and tissue regeneration.

Ultrasonic therapy is generally considered safe when performed by a trained healthcare professional. However, it should be avoided in certain situations, such as over areas with malignant tumors, infected tissues, or near metal implants (due to the risk of heating). Pregnant women should also avoid therapeutic ultrasound, especially during the first trimester, due to potential risks to fetal development.

Carboxypeptidase U is also known as thiol protease or thiol carboxypeptidase. It is a type of enzyme that belongs to the peptidase family, specifically the serine proteases. This enzyme plays a role in the regulation of blood pressure by cleaving and inactivating bradykinin, a potent vasodilator peptide. Carboxypeptidase U is primarily produced in the kidneys and is released into the circulation in response to various stimuli, such as renin and angiotensin II. It functions by removing the C-terminal arginine residue from bradykinin, thereby reducing its biological activity and helping to maintain blood pressure homeostasis.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Carotid artery thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) inside the carotid artery, which is one of the major blood vessels that supplies oxygenated blood to the head and neck. This condition can lead to serious complications such as a stroke or transient ischemic attack (TIA), also known as a "mini-stroke," if the clot dislodges and travels to the brain, blocking the flow of blood and oxygen.

Carotid artery thrombosis can result from various factors, including atherosclerosis (the buildup of fats, cholesterol, and other substances in the artery walls), hypertension (high blood pressure), diabetes, smoking, and genetic predisposition. Symptoms may include neck pain or stiffness, weakness or numbness in the face or limbs, difficulty speaking or understanding speech, vision problems, and sudden severe headaches. Diagnosis typically involves imaging tests such as ultrasound, CT angiography, or MRI angiography. Treatment options may include anticoagulant or antiplatelet medications, endovascular procedures to remove the clot, or surgery to clean out the artery (carotid endarterectomy).

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Intra-arterial infusion is a medical procedure in which a liquid medication or fluid is delivered directly into an artery. This technique is used to deliver drugs directly to a specific organ or region of the body, bypassing the usual systemic circulation and allowing for higher concentrations of the drug to reach the target area. It is often used in cancer treatment to deliver chemotherapeutic agents directly to tumors, as well as in other conditions such as severe infections or inflammation.

Intra-arterial infusions are typically administered through a catheter that is inserted into an artery, usually under the guidance of imaging techniques such as fluoroscopy, CT, or MRI. The procedure requires careful monitoring and precise control to ensure proper placement of the catheter and accurate delivery of the medication.

It's important to note that intra-arterial infusions are different from intra venous (IV) infusions, where medications are delivered into a vein instead of an artery. The choice between intra-arterial and intra-venous infusion depends on various factors such as the type of medication being used, the location of the target area, and the patient's overall medical condition.

Antifibrinolytic agents are a class of medications that inhibit the breakdown of blood clots. They work by blocking the action of enzymes called plasminogen activators, which convert plasminogen to plasmin, the main enzyme responsible for breaking down fibrin, a protein that forms the framework of a blood clot.

By preventing the conversion of plasminogen to plasmin, antifibrinolytic agents help to stabilize existing blood clots and prevent their premature dissolution. These medications are often used in clinical settings where excessive bleeding is a concern, such as during or after surgery, childbirth, or trauma.

Examples of antifibrinolytic agents include tranexamic acid, aminocaproic acid, and epsilon-aminocaproic acid. While these medications can be effective in reducing bleeding, they also carry the risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, due to their pro-coagulant effects. Therefore, they should be used with caution and only under the close supervision of a healthcare provider.

Vitronectin is a glycoprotein found in various biological fluids, including blood plasma. It has multiple functions in the body, such as participating in blood clotting (as a cofactor for the protease thrombin), inhibiting the complement system, and binding to cell surfaces and the extracellular matrix. Vitronectin can also interact with several other molecules, including heparin, collagen, and the cytoskeleton. It is involved in various biological processes, such as cell adhesion, migration, and protection against apoptosis (programmed cell death).

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Intra-arterial injection is a type of medical procedure where a medication or contrast agent is delivered directly into an artery. This technique is used for various therapeutic and diagnostic purposes.

For instance, intra-arterial chemotherapy may be used to deliver cancer drugs directly to the site of a tumor, while intra-arterial thrombolysis involves the administration of clot-busting medications to treat arterial blockages caused by blood clots. Intra-arterial injections are also used in diagnostic imaging procedures such as angiography, where a contrast agent is injected into an artery to visualize the blood vessels and identify any abnormalities.

It's important to note that intra-arterial injections require precise placement of the needle or catheter into the artery, and are typically performed by trained medical professionals using specialized equipment.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

The umbilical veins are blood vessels in the umbilical cord that carry oxygenated and nutrient-rich blood from the mother to the developing fetus during pregnancy. There are typically two umbilical veins, one of which usually degenerates and becomes obliterated, leaving a single functional vein. This remaining vein is known as the larger umbilical vein or the venous duct. It enters the fetal abdomen through the umbilicus and passes through the liver, where it branches off to form the portal sinus. Ultimately, the blood from the umbilical vein mixes with the blood from the inferior vena cava and is pumped to the heart through the right atrium.

It's important to note that after birth, the umbilical veins are no longer needed and undergo involution, becoming the ligamentum teres in the adult.

Cerebral infarction, also known as a "stroke" or "brain attack," is the sudden death of brain cells caused by the interruption of their blood supply. It is most commonly caused by a blockage in one of the blood vessels supplying the brain (an ischemic stroke), but can also result from a hemorrhage in or around the brain (a hemorrhagic stroke).

Ischemic strokes occur when a blood clot or other particle blocks a cerebral artery, cutting off blood flow to a part of the brain. The lack of oxygen and nutrients causes nearby brain cells to die. Hemorrhagic strokes occur when a weakened blood vessel ruptures, causing bleeding within or around the brain. This bleeding can put pressure on surrounding brain tissues, leading to cell death.

Symptoms of cerebral infarction depend on the location and extent of the affected brain tissue but may include sudden weakness or numbness in the face, arm, or leg; difficulty speaking or understanding speech; vision problems; loss of balance or coordination; and severe headache with no known cause. Immediate medical attention is crucial for proper diagnosis and treatment to minimize potential long-term damage or disability.

Blood coagulation factors, also known as clotting factors, are a group of proteins that play a crucial role in the blood coagulation process. They are essential for maintaining hemostasis, which is the body's ability to stop bleeding after injury.

There are 13 known blood coagulation factors, and they are designated by Roman numerals I through XIII. These factors are produced in the liver and are normally present in an inactive form in the blood. When there is an injury to a blood vessel, the coagulation process is initiated, leading to the activation of these factors in a specific order.

The coagulation cascade involves two pathways: the intrinsic and extrinsic pathways. The intrinsic pathway is activated when there is damage to the blood vessel itself, while the extrinsic pathway is activated by tissue factor released from damaged tissues. Both pathways converge at the common pathway, leading to the formation of a fibrin clot.

Blood coagulation factors work together in a complex series of reactions that involve activation, binding, and proteolysis. When one factor is activated, it activates the next factor in the cascade, and so on. This process continues until a stable fibrin clot is formed.

Deficiencies or abnormalities in blood coagulation factors can lead to bleeding disorders such as hemophilia or thrombosis. Hemophilia is a genetic disorder that affects one or more of the coagulation factors, leading to excessive bleeding and difficulty forming clots. Thrombosis, on the other hand, occurs when there is an abnormal formation of blood clots in the blood vessels, which can lead to serious complications such as stroke or pulmonary embolism.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

A thrombectomy is a medical procedure that involves the removal of a blood clot (thrombus) from a blood vessel. This is typically performed to restore blood flow in cases where the clot is causing significant blockage, which can lead to serious complications such as tissue damage or organ dysfunction.

During a thrombectomy, a surgeon makes an incision and accesses the affected blood vessel, often with the help of imaging guidance. Specialized tools are then used to extract the clot, after which the blood vessel is usually repaired. Thrombectomies can be performed on various blood vessels throughout the body, including those in the brain, heart, lungs, and limbs.

This procedure may be recommended for patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of stroke, depending on the specific circumstances and the patient's overall health. It is generally considered when anticoagulation therapy or clot-dissolving medications are not sufficient or appropriate to treat the blood clot.

Glycoproteins are complex proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. These glycans are linked to the protein through asparagine residues (N-linked) or serine/threonine residues (O-linked). Glycoproteins play crucial roles in various biological processes, including cell recognition, cell-cell interactions, cell adhesion, and signal transduction. They are widely distributed in nature and can be found on the outer surface of cell membranes, in extracellular fluids, and as components of the extracellular matrix. The structure and composition of glycoproteins can vary significantly depending on their function and location within an organism.

SERPINs are an acronym for "serine protease inhibitors." They are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins. SERPINs are found in various tissues and body fluids, including blood, and play important roles in regulating biological processes such as inflammation, blood clotting, and cell death. They do this by forming covalent complexes with their target proteases, thereby preventing them from carrying out their proteolytic activities. Mutations in SERPIN genes have been associated with several genetic disorders, including emphysema, cirrhosis, and dementia.

Medical Definition:

Matrix metalloproteinase 9 (MMP-9), also known as gelatinase B or 92 kDa type IV collagenase, is a member of the matrix metalloproteinase family. These enzymes are involved in degrading and remodeling the extracellular matrix (ECM) components, playing crucial roles in various physiological and pathological processes such as wound healing, tissue repair, and tumor metastasis.

MMP-9 is secreted as an inactive zymogen and activated upon removal of its propeptide domain. It can degrade several ECM proteins, including type IV collagen, elastin, fibronectin, and gelatin. MMP-9 has been implicated in numerous diseases, such as cancer, rheumatoid arthritis, neurological disorders, and cardiovascular diseases. Its expression is regulated at the transcriptional, translational, and post-translational levels, and its activity can be controlled by endogenous inhibitors called tissue inhibitors of metalloproteinases (TIMPs).

Cerebrovascular disorders are a group of medical conditions that affect the blood vessels of the brain. These disorders can be caused by narrowing, blockage, or rupture of the blood vessels, leading to decreased blood flow and oxygen supply to the brain. The most common types of cerebrovascular disorders include:

1. Stroke: A stroke occurs when a blood vessel in the brain becomes blocked or bursts, causing a lack of oxygen and nutrients to reach brain cells. This can lead to permanent damage or death of brain tissue.
2. Transient ischemic attack (TIA): Also known as a "mini-stroke," a TIA occurs when blood flow to the brain is temporarily blocked, often by a blood clot. Symptoms may last only a few minutes to a few hours and typically resolve on their own. However, a TIA is a serious warning sign that a full-blown stroke may occur in the future.
3. Aneurysm: An aneurysm is a weakened or bulging area in the wall of a blood vessel. If left untreated, an aneurysm can rupture and cause bleeding in the brain.
4. Arteriovenous malformation (AVM): An AVM is a tangled mass of abnormal blood vessels that connect arteries and veins. This can lead to bleeding in the brain or stroke.
5. Carotid stenosis: Carotid stenosis occurs when the carotid arteries, which supply blood to the brain, become narrowed or blocked due to plaque buildup. This can increase the risk of stroke.
6. Vertebrobasilar insufficiency: This condition occurs when the vertebral and basilar arteries, which supply blood to the back of the brain, become narrowed or blocked. This can lead to symptoms such as dizziness, vertigo, and difficulty swallowing.

Cerebrovascular disorders are a leading cause of disability and death worldwide. Risk factors for these conditions include age, high blood pressure, smoking, diabetes, high cholesterol, and family history. Treatment may involve medications, surgery, or lifestyle changes to reduce the risk of further complications.

Myocardial infarction (MI), also known as a heart attack, is a medical condition characterized by the death of a segment of heart muscle (myocardium) due to the interruption of its blood supply. This interruption is most commonly caused by the blockage of a coronary artery by a blood clot formed on the top of an atherosclerotic plaque, which is a buildup of cholesterol and other substances in the inner lining of the artery.

The lack of oxygen and nutrients supply to the heart muscle tissue results in damage or death of the cardiac cells, causing the affected area to become necrotic. The extent and severity of the MI depend on the size of the affected area, the duration of the occlusion, and the presence of collateral circulation.

Symptoms of a myocardial infarction may include chest pain or discomfort, shortness of breath, nausea, lightheadedness, and sweating. Immediate medical attention is necessary to restore blood flow to the affected area and prevent further damage to the heart muscle. Treatment options for MI include medications, such as thrombolytics, antiplatelet agents, and pain relievers, as well as procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Von Willebrand factor (vWF) is a large multimeric glycoprotein that plays a crucial role in hemostasis, the process which leads to the cessation of bleeding and the formation of a blood clot. It was named after Erik Adolf von Willebrand, a Finnish physician who first described the disorder associated with its deficiency, known as von Willebrand disease (vWD).

The primary functions of vWF include:

1. Platelet adhesion and aggregation: vWF mediates the initial attachment of platelets to damaged blood vessel walls by binding to exposed collagen fibers and then interacting with glycoprotein Ib (GPIb) receptors on the surface of platelets, facilitating platelet adhesion. Subsequently, vWF also promotes platelet-platelet interactions (aggregation) through its interaction with platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptors under high shear stress conditions found in areas of turbulent blood flow, such as arterioles and the capillary bed.

2. Transport and stabilization of coagulation factor VIII: vWF serves as a carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation and maintaining its stability in circulation. This interaction between vWF and FVIII is essential for the proper functioning of the coagulation cascade, particularly in the context of vWD, where impaired FVIII function can lead to bleeding disorders.

3. Wound healing: vWF contributes to wound healing by promoting platelet adhesion and aggregation at the site of injury, which facilitates the formation of a provisional fibrin-based clot that serves as a scaffold for tissue repair and regeneration.

In summary, von Willebrand factor is a vital hemostatic protein involved in platelet adhesion, aggregation, coagulation factor VIII stabilization, and wound healing. Deficiencies or dysfunctions in vWF can lead to bleeding disorders such as von Willebrand disease.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Electrophoresis, polyacrylamide gel (EPG) is a laboratory technique used to separate and analyze complex mixtures of proteins or nucleic acids (DNA or RNA) based on their size and electrical charge. This technique utilizes a matrix made of cross-linked polyacrylamide, a type of gel, which provides a stable and uniform environment for the separation of molecules.

In this process:

1. The polyacrylamide gel is prepared by mixing acrylamide monomers with a cross-linking agent (bis-acrylamide) and a catalyst (ammonium persulfate) in the presence of a buffer solution.
2. The gel is then poured into a mold and allowed to polymerize, forming a solid matrix with uniform pore sizes that depend on the concentration of acrylamide used. Higher concentrations result in smaller pores, providing better resolution for separating smaller molecules.
3. Once the gel has set, it is placed in an electrophoresis apparatus containing a buffer solution. Samples containing the mixture of proteins or nucleic acids are loaded into wells on the top of the gel.
4. An electric field is applied across the gel, causing the negatively charged molecules to migrate towards the positive electrode (anode) while positively charged molecules move toward the negative electrode (cathode). The rate of migration depends on the size, charge, and shape of the molecules.
5. Smaller molecules move faster through the gel matrix and will migrate farther from the origin compared to larger molecules, resulting in separation based on size. Proteins and nucleic acids can be selectively stained after electrophoresis to visualize the separated bands.

EPG is widely used in various research fields, including molecular biology, genetics, proteomics, and forensic science, for applications such as protein characterization, DNA fragment analysis, cloning, mutation detection, and quality control of nucleic acid or protein samples.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Thrombomodulin is a protein that is found on the surface of endothelial cells, which line the interior surface of blood vessels. It plays an important role in the regulation of blood coagulation (clotting) and the activation of natural anticoagulant pathways. Thrombomodulin binds to thrombin, a protein involved in blood clotting, and changes its function from promoting coagulation to inhibiting it. This interaction also activates protein C, an important anticoagulant protein, which helps to prevent the excessive formation of blood clots. Thrombomodulin also has anti-inflammatory properties and is involved in the maintenance of the integrity of the endothelial cell lining.

Transcranial Doppler ultrasonography is a non-invasive diagnostic technique that uses high-frequency sound waves to visualize and measure the velocity of blood flow in the cerebral arteries located in the skull. This imaging modality employs the Doppler effect, which describes the change in frequency of sound waves as they reflect off moving red blood cells. By measuring the frequency shift of the reflected ultrasound waves, the velocity and direction of blood flow can be determined.

Transcranial Doppler ultrasonography is primarily used to assess cerebrovascular circulation and detect abnormalities such as stenosis (narrowing), occlusion (blockage), or embolism (obstruction) in the intracranial arteries. It can also help monitor patients with conditions like sickle cell disease, vasospasm following subarachnoid hemorrhage, and evaluate the effectiveness of treatments such as thrombolysis or angioplasty. The procedure is typically performed by placing a transducer on the patient's skull after applying a coupling gel, and it does not involve radiation exposure or contrast agents.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

Clot retraction is the process that occurs during blood clotting where the platelets in the blood contract and pull together the edges of the clot, causing it to shrink. This process helps to seal off injured blood vessels and prevent further bleeding. Clot retraction also aids in the healing process by helping to remove damaged tissue and debris from the wound site. The proteins in the blood, called fibrin, form a mesh that traps red and white blood cells and platelets, creating a clot. As the platelets contract, they pull on the fibrin mesh, causing it to tighten and the clot to shrink. This process is an important part of the body's natural healing response to injury.

Protein binding, in the context of medical and biological sciences, refers to the interaction between a protein and another molecule (known as the ligand) that results in a stable complex. This process is often reversible and can be influenced by various factors such as pH, temperature, and concentration of the involved molecules.

In clinical chemistry, protein binding is particularly important when it comes to drugs, as many of them bind to proteins (especially albumin) in the bloodstream. The degree of protein binding can affect a drug's distribution, metabolism, and excretion, which in turn influence its therapeutic effectiveness and potential side effects.

Protein-bound drugs may be less available for interaction with their target tissues, as only the unbound or "free" fraction of the drug is active. Therefore, understanding protein binding can help optimize dosing regimens and minimize adverse reactions.

The brain is the central organ of the nervous system, responsible for receiving and processing sensory information, regulating vital functions, and controlling behavior, movement, and cognition. It is divided into several distinct regions, each with specific functions:

1. Cerebrum: The largest part of the brain, responsible for higher cognitive functions such as thinking, learning, memory, language, and perception. It is divided into two hemispheres, each controlling the opposite side of the body.
2. Cerebellum: Located at the back of the brain, it is responsible for coordinating muscle movements, maintaining balance, and fine-tuning motor skills.
3. Brainstem: Connects the cerebrum and cerebellum to the spinal cord, controlling vital functions such as breathing, heart rate, and blood pressure. It also serves as a relay center for sensory information and motor commands between the brain and the rest of the body.
4. Diencephalon: A region that includes the thalamus (a major sensory relay station) and hypothalamus (regulates hormones, temperature, hunger, thirst, and sleep).
5. Limbic system: A group of structures involved in emotional processing, memory formation, and motivation, including the hippocampus, amygdala, and cingulate gyrus.

The brain is composed of billions of interconnected neurons that communicate through electrical and chemical signals. It is protected by the skull and surrounded by three layers of membranes called meninges, as well as cerebrospinal fluid that provides cushioning and nutrients.

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

I believe there may be some confusion in your question. "Rabbits" is a common name used to refer to the Lagomorpha species, particularly members of the family Leporidae. They are small mammals known for their long ears, strong legs, and quick reproduction.

However, if you're referring to "rabbits" in a medical context, there is a term called "rabbit syndrome," which is a rare movement disorder characterized by repetitive, involuntary movements of the fingers, resembling those of a rabbit chewing. It is also known as "finger-chewing chorea." This condition is usually associated with certain medications, particularly antipsychotics, and typically resolves when the medication is stopped or adjusted.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

Hepatic Veno-Occlusive Disease (VOD), also known as Sinusoidal Obstruction Syndrome (SOS), is a medical condition characterized by the obstruction or blockage of the small veins (venules) in the liver. This results in the backup of blood in the liver, leading to swelling and damage to the liver cells.

The obstruction is usually caused by the injury and inflammation of the endothelial cells lining the venules, which can be triggered by various factors such as chemotherapy drugs, radiation therapy, bone marrow transplantation, or exposure to certain toxins. The damage to the liver can lead to symptoms such as fluid accumulation in the abdomen (ascites), enlarged liver, jaundice, and in severe cases, liver failure.

The diagnosis of VOD/SOS is typically made based on a combination of clinical signs, symptoms, and imaging studies, such as ultrasound or CT scan. In some cases, a liver biopsy may be necessary to confirm the diagnosis. Treatment for VOD/SOS is primarily supportive, with the goal of managing symptoms and preventing complications. This may include medications to reduce swelling, improve liver function, and prevent infection. In severe cases, liver transplantation may be considered as a last resort.

In the context of medical and biological sciences, a "binding site" refers to a specific location on a protein, molecule, or cell where another molecule can attach or bind. This binding interaction can lead to various functional changes in the original protein or molecule. The other molecule that binds to the binding site is often referred to as a ligand, which can be a small molecule, ion, or even another protein.

The binding between a ligand and its target binding site can be specific and selective, meaning that only certain ligands can bind to particular binding sites with high affinity. This specificity plays a crucial role in various biological processes, such as signal transduction, enzyme catalysis, or drug action.

In the case of drug development, understanding the location and properties of binding sites on target proteins is essential for designing drugs that can selectively bind to these sites and modulate protein function. This knowledge can help create more effective and safer therapeutic options for various diseases.

Enzyme activation refers to the process by which an enzyme becomes biologically active and capable of carrying out its specific chemical or biological reaction. This is often achieved through various post-translational modifications, such as proteolytic cleavage, phosphorylation, or addition of cofactors or prosthetic groups to the enzyme molecule. These modifications can change the conformation or structure of the enzyme, exposing or creating a binding site for the substrate and allowing the enzymatic reaction to occur.

For example, in the case of proteolytic cleavage, an inactive precursor enzyme, known as a zymogen, is cleaved into its active form by a specific protease. This is seen in enzymes such as trypsin and chymotrypsin, which are initially produced in the pancreas as inactive precursors called trypsinogen and chymotrypsinogen, respectively. Once they reach the small intestine, they are activated by enteropeptidase, a protease that cleaves a specific peptide bond, releasing the active enzyme.

Phosphorylation is another common mechanism of enzyme activation, where a phosphate group is added to a specific serine, threonine, or tyrosine residue on the enzyme by a protein kinase. This modification can alter the conformation of the enzyme and create a binding site for the substrate, allowing the enzymatic reaction to occur.

Enzyme activation is a crucial process in many biological pathways, as it allows for precise control over when and where specific reactions take place. It also provides a mechanism for regulating enzyme activity in response to various signals and stimuli, such as hormones, neurotransmitters, or changes in the intracellular environment.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

A Severity of Illness Index is a measurement tool used in healthcare to assess the severity of a patient's condition and the risk of mortality or other adverse outcomes. These indices typically take into account various physiological and clinical variables, such as vital signs, laboratory values, and co-morbidities, to generate a score that reflects the patient's overall illness severity.

Examples of Severity of Illness Indices include the Acute Physiology and Chronic Health Evaluation (APACHE) system, the Simplified Acute Physiology Score (SAPS), and the Mortality Probability Model (MPM). These indices are often used in critical care settings to guide clinical decision-making, inform prognosis, and compare outcomes across different patient populations.

It is important to note that while these indices can provide valuable information about a patient's condition, they should not be used as the sole basis for clinical decision-making. Rather, they should be considered in conjunction with other factors, such as the patient's overall clinical presentation, treatment preferences, and goals of care.

Coronary thrombosis is a medical condition that refers to the formation of a blood clot (thrombus) inside a coronary artery, which supplies oxygenated blood to the heart muscle. The development of a thrombus can partially or completely obstruct blood flow, leading to insufficient oxygen supply to the heart muscle. This can cause chest pain (angina) or a heart attack (myocardial infarction), depending on the severity and duration of the blockage.

Coronary thrombosis often results from the rupture of an atherosclerotic plaque, a buildup of cholesterol, fat, calcium, and other substances in the inner lining (endothelium) of the coronary artery. The ruptured plaque exposes the underlying tissue to the bloodstream, triggering the coagulation cascade and resulting in the formation of a thrombus.

Immediate medical attention is crucial for managing coronary thrombosis, as timely treatment can help restore blood flow, prevent further damage to the heart muscle, and reduce the risk of complications such as heart failure or life-threatening arrhythmias. Treatment options may include medications, such as antiplatelet agents, anticoagulants, and thrombolytic drugs, or interventional procedures like angioplasty and stenting to open the blocked artery. In some cases, surgical intervention, such as coronary artery bypass grafting (CABG), may be necessary.

A "knockout" mouse is a genetically engineered mouse in which one or more genes have been deleted or "knocked out" using molecular biology techniques. This allows researchers to study the function of specific genes and their role in various biological processes, as well as potential associations with human diseases. The mice are generated by introducing targeted DNA modifications into embryonic stem cells, which are then used to create a live animal. Knockout mice have been widely used in biomedical research to investigate gene function, disease mechanisms, and potential therapeutic targets.

A hematoma is defined as a localized accumulation of blood in a tissue, organ, or body space caused by a break in the wall of a blood vessel. This can result from various causes such as trauma, surgery, or certain medical conditions that affect coagulation. The severity and size of a hematoma may vary depending on the location and extent of the bleeding. Symptoms can include swelling, pain, bruising, and decreased mobility in the affected area. Treatment options depend on the size and location of the hematoma but may include observation, compression, ice, elevation, or in some cases, surgical intervention.

Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) is a large transmembrane receptor protein that belongs to the low-density lipoprotein receptor family. It plays a crucial role in various biological processes, including cellular signaling, endocytosis, and intracellular trafficking of ligands. LRP1 is widely expressed in many tissues, particularly in the brain, liver, and vascular endothelial cells.

LRP1 interacts with a diverse array of ligands, such as extracellular matrix proteins, apolipoproteins, proteinases, proteinase inhibitors, and various pathogen-associated molecules. The receptor is involved in the clearance of these ligands from the extracellular space through endocytosis, followed by intracellular degradation or recycling.

In the context of lipid metabolism, LRP1 has been implicated in the cellular uptake and degradation of Apolipoprotein E (ApoE)-containing lipoproteins, which are involved in the reverse transport of cholesterol from peripheral tissues to the liver. Dysregulation of LRP1 function has been linked to several diseases, including atherosclerosis, Alzheimer's disease, and various neurological disorders.

In summary, Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) is a multifunctional transmembrane receptor that plays essential roles in cellular signaling, endocytosis, and intracellular trafficking of various ligands. Its dysfunction has been implicated in several diseases related to lipid metabolism, neurodegeneration, and neurological disorders.

The Blood-Brain Barrier (BBB) is a highly specialized, selective interface between the central nervous system (CNS) and the circulating blood. It is formed by unique endothelial cells that line the brain's capillaries, along with tight junctions, astrocytic foot processes, and pericytes, which together restrict the passage of substances from the bloodstream into the CNS. This barrier serves to protect the brain from harmful agents and maintain a stable environment for proper neural function. However, it also poses a challenge in delivering therapeutics to the CNS, as most large and hydrophilic molecules cannot cross the BBB.

Brain infarction, also known as cerebral infarction, is a type of stroke that occurs when blood flow to a part of the brain is blocked, often by a blood clot. This results in oxygen and nutrient deprivation to the brain tissue, causing it to become damaged or die. The effects of a brain infarction depend on the location and extent of the damage, but can include weakness, numbness, paralysis, speech difficulties, memory loss, and other neurological symptoms.

Brain infarctions are often caused by underlying medical conditions such as atherosclerosis, atrial fibrillation, or high blood pressure. Treatment typically involves addressing the underlying cause of the blockage, administering medications to dissolve clots or prevent further clotting, and providing supportive care to manage symptoms and prevent complications.

'Gene expression regulation' refers to the processes that control whether, when, and where a particular gene is expressed, meaning the production of a specific protein or functional RNA encoded by that gene. This complex mechanism can be influenced by various factors such as transcription factors, chromatin remodeling, DNA methylation, non-coding RNAs, and post-transcriptional modifications, among others. Proper regulation of gene expression is crucial for normal cellular function, development, and maintaining homeostasis in living organisms. Dysregulation of gene expression can lead to various diseases, including cancer and genetic disorders.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Cerebral angiography is a medical procedure that involves taking X-ray images of the blood vessels in the brain after injecting a contrast dye into them. This procedure helps doctors to diagnose and treat various conditions affecting the blood vessels in the brain, such as aneurysms, arteriovenous malformations, and stenosis (narrowing of the blood vessels).

During the procedure, a catheter is inserted into an artery in the leg and threaded through the body to the blood vessels in the neck or brain. The contrast dye is then injected through the catheter, and X-ray images are taken to visualize the blood flow through the brain's blood vessels.

Cerebral angiography provides detailed images of the blood vessels in the brain, allowing doctors to identify any abnormalities or blockages that may be causing symptoms or increasing the risk of stroke. Based on the results of the cerebral angiography, doctors can develop a treatment plan to address these issues and prevent further complications.

Pipicolic acid is not a term that refers to a specific medical condition or disease. Instead, it is a metabolite that is involved in the body's metabolic processes.

Pipicolic acid is a type of organic compound called a cyclic amino acid, which is derived from the amino acid lysine. It is produced in the liver and is excreted in urine. Pipicolic acid has been found to have various functions in the body, including regulating the metabolism of lipids and bile acids.

Abnormal levels of pipicolic acid in the body may be associated with certain medical conditions, such as liver disease or genetic disorders that affect amino acid metabolism. However, pipicolic acid is not typically used as a diagnostic marker for these conditions.

In summary, pipicolic acid is a cyclic amino acid produced in the liver and involved in various metabolic processes in the body. Abnormal levels of pipicolic acid may be associated with certain medical conditions but are not typically used as diagnostic markers.

Neuroprotective agents are substances that protect neurons or nerve cells from damage, degeneration, or death caused by various factors such as trauma, inflammation, oxidative stress, or excitotoxicity. These agents work through different mechanisms, including reducing the production of free radicals, inhibiting the release of glutamate (a neurotransmitter that can cause cell damage in high concentrations), promoting the growth and survival of neurons, and preventing apoptosis (programmed cell death). Neuroprotective agents have been studied for their potential to treat various neurological disorders, including stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. However, more research is needed to fully understand their mechanisms of action and to develop effective therapies.

Enzyme precursors are typically referred to as zymogens or proenzymes. These are inactive forms of enzymes that can be activated under specific conditions. When the need for the enzyme's function arises, the proenzyme is converted into its active form through a process called proteolysis, where it is cleaved by another enzyme. This mechanism helps control and regulate the activation of certain enzymes in the body, preventing unwanted or premature reactions. A well-known example of an enzyme precursor is trypsinogen, which is converted into its active form, trypsin, in the digestive system.

Cerebral arteries refer to the blood vessels that supply oxygenated blood to the brain. These arteries branch off from the internal carotid arteries and the vertebral arteries, which combine to form the basilar artery. The major cerebral arteries include:

1. Anterior cerebral artery (ACA): This artery supplies blood to the frontal lobes of the brain, including the motor and sensory cortices responsible for movement and sensation in the lower limbs.
2. Middle cerebral artery (MCA): The MCA is the largest of the cerebral arteries and supplies blood to the lateral surface of the brain, including the temporal, parietal, and frontal lobes. It is responsible for providing blood to areas involved in motor function, sensory perception, speech, memory, and vision.
3. Posterior cerebral artery (PCA): The PCA supplies blood to the occipital lobe, which is responsible for visual processing, as well as parts of the temporal and parietal lobes.
4. Anterior communicating artery (ACoA) and posterior communicating arteries (PComAs): These are small arteries that connect the major cerebral arteries, forming an important circulatory network called the Circle of Willis. The ACoA connects the two ACAs, while the PComAs connect the ICA with the PCA and the basilar artery.

These cerebral arteries play a crucial role in maintaining proper brain function by delivering oxygenated blood to various regions of the brain. Any damage or obstruction to these arteries can lead to serious neurological conditions, such as strokes or transient ischemic attacks (TIAs).

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

The Middle Cerebral Artery (MCA) is one of the main blood vessels that supplies oxygenated blood to the brain. It arises from the internal carotid artery and divides into several branches, which supply the lateral surface of the cerebral hemisphere, including the frontal, parietal, and temporal lobes.

The MCA is responsible for providing blood flow to critical areas of the brain, such as the primary motor and sensory cortices, Broca's area (associated with speech production), Wernicke's area (associated with language comprehension), and the visual association cortex.

Damage to the MCA or its branches can result in a variety of neurological deficits, depending on the specific location and extent of the injury. These may include weakness or paralysis on one side of the body, sensory loss, language impairment, and visual field cuts.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

Bradykinin is a naturally occurring peptide in the human body, consisting of nine amino acids. It is a potent vasodilator and increases the permeability of blood vessels, causing a local inflammatory response. Bradykinin is formed from the breakdown of certain proteins, such as kininogen, by enzymes called kininases or proteases, including kallikrein. It plays a role in several physiological processes, including pain transmission, blood pressure regulation, and the immune response. In some pathological conditions, such as hereditary angioedema, bradykinin levels can increase excessively, leading to symptoms like swelling, redness, and pain.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Community hospitals are healthcare facilities that provide a range of medical services to the local population in a given geographic area. They are typically smaller than major teaching or tertiary care hospitals and offer a more personalized level of care. The services provided by community hospitals may include general medical, surgical, obstetrical, and pediatric care, as well as diagnostic and therapeutic services such as laboratory testing, imaging, and rehabilitation.

Community hospitals often play an important role in providing access to healthcare for underserved populations and may offer specialized programs to address the specific health needs of the communities they serve. They may also collaborate with other healthcare providers, such as primary care physicians, specialists, and long-term care facilities, to provide coordinated care and improve outcomes for patients.

Overall, community hospitals are an essential component of the healthcare system and play a vital role in providing high-quality, accessible care to local populations.

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Peptide hydrolases, also known as proteases or peptidases, are a group of enzymes that catalyze the hydrolysis of peptide bonds in proteins and peptides. They play a crucial role in various biological processes such as protein degradation, digestion, cell signaling, and regulation of various physiological functions. Based on their catalytic mechanism and the specificity for the peptide bond, they are classified into several types, including serine proteases, cysteine proteases, aspartic proteases, and metalloproteases. These enzymes have important clinical applications in the diagnosis and treatment of various diseases, such as cancer, viral infections, and inflammatory disorders.

The Predictive Value of Tests, specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), are measures used in diagnostic tests to determine the probability that a positive or negative test result is correct.

Positive Predictive Value (PPV) is the proportion of patients with a positive test result who actually have the disease. It is calculated as the number of true positives divided by the total number of positive results (true positives + false positives). A higher PPV indicates that a positive test result is more likely to be a true positive, and therefore the disease is more likely to be present.

Negative Predictive Value (NPV) is the proportion of patients with a negative test result who do not have the disease. It is calculated as the number of true negatives divided by the total number of negative results (true negatives + false negatives). A higher NPV indicates that a negative test result is more likely to be a true negative, and therefore the disease is less likely to be present.

The predictive value of tests depends on the prevalence of the disease in the population being tested, as well as the sensitivity and specificity of the test. A test with high sensitivity and specificity will generally have higher predictive values than a test with low sensitivity and specificity. However, even a highly sensitive and specific test can have low predictive values if the prevalence of the disease is low in the population being tested.

The forearm is the region of the upper limb between the elbow and the wrist. It consists of two bones, the radius and ulna, which are located side by side and run parallel to each other. The forearm is responsible for movements such as flexion, extension, supination, and pronation of the hand and wrist.

Iridocorneal Endothelial Syndrome (ICES) is a rare, progressive condition that affects the eye's iris and endothelium - the cell layer lining the inner surface of the cornea. ICE syndrome is typically characterized by three distinct clinical presentations: iris nevus (or Cogan-Reese) syndrome, Chandler's syndrome, and essential iris atrophy.

Common features of ICE syndrome include:

1. Progressive distortion and contraction of the iris (iris atrophy or hole formation).
2. Visible deposits on the surface of the iris (iris nevus).
3. Swelling and deterioration of the corneal endothelium, which can lead to decreased vision, corneal edema, and clouding.
4. Glaucoma development due to blockage of the eye's drainage angle by the iris changes or peripheral anterior synechiae (adhesions between the iris and cornea).

ICES primarily affects young to middle-aged women and is typically unilateral (affecting one eye). The exact cause of ICE syndrome remains unknown, but it's believed to be related to abnormalities in the endothelial cell layer. Currently, there is no definitive treatment for ICE syndrome. Management focuses on addressing symptoms and complications such as controlling intraocular pressure and monitoring for glaucoma progression.

Northern blotting is a laboratory technique used in molecular biology to detect and analyze specific RNA molecules (such as mRNA) in a mixture of total RNA extracted from cells or tissues. This technique is called "Northern" blotting because it is analogous to the Southern blotting method, which is used for DNA detection.

The Northern blotting procedure involves several steps:

1. Electrophoresis: The total RNA mixture is first separated based on size by running it through an agarose gel using electrical current. This separates the RNA molecules according to their length, with smaller RNA fragments migrating faster than larger ones.

2. Transfer: After electrophoresis, the RNA bands are denatured (made single-stranded) and transferred from the gel onto a nitrocellulose or nylon membrane using a technique called capillary transfer or vacuum blotting. This step ensures that the order and relative positions of the RNA fragments are preserved on the membrane, similar to how they appear in the gel.

3. Cross-linking: The RNA is then chemically cross-linked to the membrane using UV light or heat treatment, which helps to immobilize the RNA onto the membrane and prevent it from washing off during subsequent steps.

4. Prehybridization: Before adding the labeled probe, the membrane is prehybridized in a solution containing blocking agents (such as salmon sperm DNA or yeast tRNA) to minimize non-specific binding of the probe to the membrane.

5. Hybridization: A labeled nucleic acid probe, specific to the RNA of interest, is added to the prehybridization solution and allowed to hybridize (form base pairs) with its complementary RNA sequence on the membrane. The probe can be either a DNA or an RNA molecule, and it is typically labeled with a radioactive isotope (such as ³²P) or a non-radioactive label (such as digoxigenin).

6. Washing: After hybridization, the membrane is washed to remove unbound probe and reduce background noise. The washing conditions (temperature, salt concentration, and detergent concentration) are optimized based on the stringency required for specific hybridization.

7. Detection: The presence of the labeled probe is then detected using an appropriate method, depending on the type of label used. For radioactive probes, this typically involves exposing the membrane to X-ray film or a phosphorimager screen and analyzing the resulting image. For non-radioactive probes, detection can be performed using colorimetric, chemiluminescent, or fluorescent methods.

8. Data analysis: The intensity of the signal is quantified and compared to controls (such as housekeeping genes) to determine the relative expression level of the RNA of interest. This information can be used for various purposes, such as identifying differentially expressed genes in response to a specific treatment or comparing gene expression levels across different samples or conditions.

Protein C is a vitamin K-dependent protease that functions as an important regulator of coagulation and inflammation. It is a plasma protein produced in the liver that, when activated, degrades clotting factors Va and VIIIa to limit thrombus formation and prevent excessive blood clotting. Protein C also has anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and reducing endothelial cell activation. Inherited or acquired deficiencies in Protein C can lead to an increased risk of thrombosis, a condition characterized by abnormal blood clot formation within blood vessels.

An embolectomy is a surgical procedure to remove an embolus, which is a blockage in a blood vessel caused by a clot or air bubble that has traveled from another part of the body. During an embolectomy, the surgeon makes an incision in the affected blood vessel and removes the embolus using specialized surgical instruments. This procedure is often performed as an emergency treatment to restore blood flow and prevent tissue damage in the affected area of the body.

Thrombophlebitis is a medical condition characterized by the inflammation and clotting of blood in a vein, usually in the legs. The term thrombophlebitis comes from two words: "thrombo" which means blood clot, and "phlebitis" which refers to inflammation of the vein.

The condition can occur in superficial or deep veins. Superficial thrombophlebitis affects the veins just below the skin's surface, while deep vein thrombophlebitis (DVT) occurs in the deeper veins. DVT is a more serious condition as it can lead to complications such as pulmonary embolism if the blood clot breaks off and travels to the lungs.

Symptoms of thrombophlebitis may include redness, warmth, pain, swelling, or discomfort in the affected area. In some cases, there may be visible surface veins that are hard, tender, or ropy to touch. If left untreated, thrombophlebitis can lead to chronic venous insufficiency and other long-term complications. Treatment typically involves medications such as anticoagulants, antiplatelet agents, or thrombolytics, along with compression stockings and other supportive measures.

Blood coagulation tests, also known as coagulation studies or clotting tests, are a series of medical tests used to evaluate the blood's ability to clot. These tests measure the functioning of various clotting factors and regulatory proteins involved in the coagulation cascade, which is a complex process that leads to the formation of a blood clot to prevent excessive bleeding.

The most commonly performed coagulation tests include:

1. Prothrombin Time (PT): Measures the time it takes for a sample of plasma to clot after the addition of calcium and tissue factor, which activates the extrinsic pathway of coagulation. The PT is reported in seconds and can be converted to an International Normalized Ratio (INR) to monitor anticoagulant therapy.
2. Activated Partial Thromboplastin Time (aPTT): Measures the time it takes for a sample of plasma to clot after the addition of calcium, phospholipid, and a contact activator, which activates the intrinsic pathway of coagulation. The aPTT is reported in seconds and is used to monitor heparin therapy.
3. Thrombin Time (TT): Measures the time it takes for a sample of plasma to clot after the addition of thrombin, which directly converts fibrinogen to fibrin. The TT is reported in seconds and can be used to detect the presence of fibrin degradation products or abnormalities in fibrinogen function.
4. Fibrinogen Level: Measures the amount of fibrinogen, a protein involved in clot formation, present in the blood. The level is reported in grams per liter (g/L) and can be used to assess bleeding risk or the effectiveness of fibrinogen replacement therapy.
5. D-dimer Level: Measures the amount of D-dimer, a protein fragment produced during the breakdown of a blood clot, present in the blood. The level is reported in micrograms per milliliter (µg/mL) and can be used to diagnose or exclude venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

These tests are important for the diagnosis, management, and monitoring of various bleeding and clotting disorders. They can help identify the underlying cause of abnormal bleeding or clotting, guide appropriate treatment decisions, and monitor the effectiveness of therapy. It is essential to interpret these test results in conjunction with a patient's clinical presentation and medical history.

Western blotting is a laboratory technique used in molecular biology to detect and quantify specific proteins in a mixture of many different proteins. This technique is commonly used to confirm the expression of a protein of interest, determine its size, and investigate its post-translational modifications. The name "Western" blotting distinguishes this technique from Southern blotting (for DNA) and Northern blotting (for RNA).

The Western blotting procedure involves several steps:

1. Protein extraction: The sample containing the proteins of interest is first extracted, often by breaking open cells or tissues and using a buffer to extract the proteins.
2. Separation of proteins by electrophoresis: The extracted proteins are then separated based on their size by loading them onto a polyacrylamide gel and running an electric current through the gel (a process called sodium dodecyl sulfate-polyacrylamide gel electrophoresis or SDS-PAGE). This separates the proteins according to their molecular weight, with smaller proteins migrating faster than larger ones.
3. Transfer of proteins to a membrane: After separation, the proteins are transferred from the gel onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane using an electric current in a process called blotting. This creates a replica of the protein pattern on the gel but now immobilized on the membrane for further analysis.
4. Blocking: The membrane is then blocked with a blocking agent, such as non-fat dry milk or bovine serum albumin (BSA), to prevent non-specific binding of antibodies in subsequent steps.
5. Primary antibody incubation: A primary antibody that specifically recognizes the protein of interest is added and allowed to bind to its target protein on the membrane. This step may be performed at room temperature or 4°C overnight, depending on the antibody's properties.
6. Washing: The membrane is washed with a buffer to remove unbound primary antibodies.
7. Secondary antibody incubation: A secondary antibody that recognizes the primary antibody (often coupled to an enzyme or fluorophore) is added and allowed to bind to the primary antibody. This step may involve using a horseradish peroxidase (HRP)-conjugated or alkaline phosphatase (AP)-conjugated secondary antibody, depending on the detection method used later.
8. Washing: The membrane is washed again to remove unbound secondary antibodies.
9. Detection: A detection reagent is added to visualize the protein of interest by detecting the signal generated from the enzyme-conjugated or fluorophore-conjugated secondary antibody. This can be done using chemiluminescent, colorimetric, or fluorescent methods.
10. Analysis: The resulting image is analyzed to determine the presence and quantity of the protein of interest in the sample.

Western blotting is a powerful technique for identifying and quantifying specific proteins within complex mixtures. It can be used to study protein expression, post-translational modifications, protein-protein interactions, and more. However, it requires careful optimization and validation to ensure accurate and reproducible results.

Transportation of patients, in a medical context, refers to the process of moving patients safely and comfortably from one location to another. This can include the movement of patients within a healthcare facility (such as from their hospital room to the radiology department for testing) or between facilities (such as from a hospital to a rehabilitation center). Patient transportation may be required for various reasons, including receiving medical treatment, undergoing diagnostic tests, attending appointments, or being discharged from the hospital.

The process of patient transportation involves careful planning and coordination to ensure the safety, comfort, and well-being of the patient during transit. It may involve the use of specialized equipment, such as stretchers, wheelchairs, or ambulances, depending on the patient's medical needs and mobility status. Trained personnel, such as paramedics, nurses, or patient care technicians, are often involved in the transportation process to monitor the patient's condition, provide medical assistance if needed, and ensure a smooth and uneventful transfer.

It is essential to follow established protocols and guidelines for patient transportation to minimize risks and ensure the best possible outcomes for patients. This includes assessing the patient's medical status, determining the appropriate mode of transportation, providing necessary care and support during transit, and communicating effectively with all parties involved in the process.

Promoter regions in genetics refer to specific DNA sequences located near the transcription start site of a gene. They serve as binding sites for RNA polymerase and various transcription factors that regulate the initiation of gene transcription. These regulatory elements help control the rate of transcription and, therefore, the level of gene expression. Promoter regions can be composed of different types of sequences, such as the TATA box and CAAT box, and their organization and composition can vary between different genes and species.

The endothelium is the thin, delicate tissue that lines the interior surface of blood vessels and lymphatic vessels. It is a single layer of cells called endothelial cells that are in contact with the blood or lymph fluid. The endothelium plays an essential role in maintaining vascular homeostasis by regulating blood flow, coagulation, platelet activation, immune function, and angiogenesis (the formation of new blood vessels). It also acts as a barrier between the vessel wall and the circulating blood or lymph fluid. Dysfunction of the endothelium has been implicated in various cardiovascular diseases, diabetes, inflammation, and cancer.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Intraocular injections are a type of medical procedure where medication is administered directly into the eye. This technique is often used to deliver drugs that treat various eye conditions, such as age-related macular degeneration, diabetic retinopathy, and endophthalmitis. The most common type of intraocular injection is an intravitreal injection, which involves injecting medication into the vitreous cavity, the space inside the eye filled with a clear gel-like substance called the vitreous humor. This procedure is typically performed by an ophthalmologist in a clinical setting and may be repeated at regular intervals depending on the condition being treated.

Molecular weight, also known as molecular mass, is the mass of a molecule. It is expressed in units of atomic mass units (amu) or daltons (Da). Molecular weight is calculated by adding up the atomic weights of each atom in a molecule. It is a useful property in chemistry and biology, as it can be used to determine the concentration of a substance in a solution, or to calculate the amount of a substance that will react with another in a chemical reaction.

"Gravity suits" is not a recognized medical term. However, in the context of space medicine and space travel, gravity suits, also known as g-suits or anti-G suits, are specialized garments worn by pilots and astronauts to prevent or reduce the negative effects of high gravitational forces (G-forces) on their bodies during high-speed maneuvers or while re-entering the Earth's atmosphere.

These suits work by applying pressure to specific areas of the body, typically around the lower abdomen and legs, to prevent the pooling of blood in those areas due to the increased G-forces. This helps maintain adequate blood flow to the brain and other vital organs, reducing the risk of loss of consciousness (G-induced Loss of Consciousness or G-LOC) and other symptoms associated with high G-forces such as blackouts, vision impairment, and disorientation.

It's important to note that gravity suits are not used as a medical treatment for any specific condition but rather as a protective measure during space travel and high-performance aviation.

"Recovery of function" is a term used in medical rehabilitation to describe the process in which an individual regains the ability to perform activities or tasks that were previously difficult or impossible due to injury, illness, or disability. This can involve both physical and cognitive functions. The goal of recovery of function is to help the person return to their prior level of independence and participation in daily activities, work, and social roles as much as possible.

Recovery of function may be achieved through various interventions such as physical therapy, occupational therapy, speech-language therapy, and other rehabilitation strategies. The specific approach used will depend on the individual's needs and the nature of their impairment. Recovery of function can occur spontaneously as the body heals, or it may require targeted interventions to help facilitate the process.

It is important to note that recovery of function does not always mean a full return to pre-injury or pre-illness levels of ability. Instead, it often refers to the person's ability to adapt and compensate for any remaining impairments, allowing them to achieve their maximum level of functional independence and quality of life.

Gene expression is the process by which the information encoded in a gene is used to synthesize a functional gene product, such as a protein or RNA molecule. This process involves several steps: transcription, RNA processing, and translation. During transcription, the genetic information in DNA is copied into a complementary RNA molecule, known as messenger RNA (mRNA). The mRNA then undergoes RNA processing, which includes adding a cap and tail to the mRNA and splicing out non-coding regions called introns. The resulting mature mRNA is then translated into a protein on ribosomes in the cytoplasm through the process of translation.

The regulation of gene expression is a complex and highly controlled process that allows cells to respond to changes in their environment, such as growth factors, hormones, and stress signals. This regulation can occur at various stages of gene expression, including transcriptional activation or repression, RNA processing, mRNA stability, and translation. Dysregulation of gene expression has been implicated in many diseases, including cancer, genetic disorders, and neurological conditions.

Brain edema is a medical condition characterized by the abnormal accumulation of fluid in the brain, leading to an increase in intracranial pressure. This can result from various causes, such as traumatic brain injury, stroke, infection, brain tumors, or inflammation. The swelling of the brain can compress vital structures, impair blood flow, and cause neurological symptoms, which may range from mild headaches to severe cognitive impairment, seizures, coma, or even death if not treated promptly and effectively.

Cerebral revascularization is a surgical procedure aimed at restoring blood flow to the brain. This is often performed in cases where there is narrowing or blockage of the cerebral arteries, a condition known as cerebrovascular disease. The most common type of cerebral revascularization is called carotid endarterectomy, which involves removing plaque buildup from the carotid artery in the neck to improve blood flow to the brain. Another type is extracranial-intracranial bypass, where a new connection is created between an external carotid artery and an intracranial artery to bypass a blockage.

Intravenous (IV) administration is a medical procedure where medication or fluids are delivered directly into a vein. This method allows for rapid absorption and distribution of the substance throughout the body. It is commonly used to provide immediate treatment in emergency situations, administer medications that cannot be given by other routes, or deliver fluids and electrolytes when someone is dehydrated.

To perform an IV administration, a healthcare professional first prepares the necessary equipment, including a sterile needle or catheter, syringe, and the medication or fluid to be administered. The site of insertion is typically on the back of the hand, inner elbow, or forearm, where veins are more visible and accessible. After cleaning and disinfecting the skin, the healthcare professional inserts the needle or catheter into the vein, securing it in place with tape or a dressing. The medication or fluid is then slowly injected or infused through the IV line.

Possible risks associated with IV administration include infection, infiltration (when the fluid leaks into surrounding tissue instead of the vein), extravasation (when the medication leaks out of the vein and causes tissue damage), and phlebitis (inflammation of the vein). Proper technique and monitoring during and after IV administration can help minimize these risks.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

Thromboplastin is a substance that activates the coagulation cascade, leading to the formation of a clot (thrombus). It's primarily found in damaged or injured tissues and blood vessels, as well as in platelets (thrombocytes). There are two types of thromboplastin:

1. Extrinsic thromboplastin (also known as tissue factor): This is a transmembrane glycoprotein that is primarily found in subendothelial cells and released upon injury to the blood vessels. It initiates the extrinsic pathway of coagulation by binding to and activating Factor VII, ultimately leading to the formation of thrombin and fibrin clots.
2. Intrinsic thromboplastin (also known as plasma thromboplastin or factor III): This term is used less frequently and refers to a labile phospholipid component present in platelet membranes, which plays a role in the intrinsic pathway of coagulation.

In clinical settings, the term "thromboplastin" often refers to reagents used in laboratory tests like the prothrombin time (PT) and activated partial thromboplastin time (aPTT). These reagents contain a source of tissue factor and calcium ions to initiate and monitor the coagulation process.

Matrix metalloproteinase 2 (MMP-2), also known as gelatinase A, is an enzyme that belongs to the matrix metalloproteinase family. MMPs are involved in the breakdown of extracellular matrix components, and MMP-2 is responsible for degrading type IV collagen, a major component of the basement membrane. This enzyme plays a crucial role in various physiological processes, including tissue remodeling, wound healing, and angiogenesis. However, its dysregulation has been implicated in several pathological conditions, such as cancer, arthritis, and cardiovascular diseases. MMP-2 is synthesized as an inactive proenzyme and requires activation by other proteases or chemical modifications before it can exert its proteolytic activity.

Factor VII, also known as proconvertin, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VII is synthesized in the liver and is activated when it comes into contact with tissue factor, which is exposed when blood vessels are damaged. Activated Factor VII then activates Factor X, leading to the formation of thrombin and ultimately a fibrin clot.

Inherited deficiencies or dysfunctions of Factor VII can lead to an increased risk of bleeding, while elevated levels of Factor VII have been associated with an increased risk of thrombosis (blood clots).

The extracellular matrix (ECM) is a complex network of biomolecules that provides structural and biochemical support to cells in tissues and organs. It is composed of various proteins, glycoproteins, and polysaccharides, such as collagens, elastin, fibronectin, laminin, and proteoglycans. The ECM plays crucial roles in maintaining tissue architecture, regulating cell behavior, and facilitating communication between cells. It provides a scaffold for cell attachment, migration, and differentiation, and helps to maintain the structural integrity of tissues by resisting mechanical stresses. Additionally, the ECM contains various growth factors, cytokines, and chemokines that can influence cellular processes such as proliferation, survival, and differentiation. Overall, the extracellular matrix is essential for the normal functioning of tissues and organs, and its dysregulation can contribute to various pathological conditions, including fibrosis, cancer, and degenerative diseases.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

Pancreatic elastase is a type of elastase that is specifically produced by the pancreas. It is an enzyme that helps in digesting proteins found in the food we eat. Pancreatic elastase breaks down elastin, a protein that provides elasticity to tissues and organs in the body.

In clinical practice, pancreatic elastase is often measured in stool samples as a diagnostic tool to assess exocrine pancreatic function. Low levels of pancreatic elastase in stool may indicate malabsorption or exocrine pancreatic insufficiency, which can be caused by various conditions such as chronic pancreatitis, cystic fibrosis, or pancreatic cancer.

Cerebrovascular circulation refers to the network of blood vessels that supply oxygenated blood and nutrients to the brain tissue, and remove waste products. It includes the internal carotid arteries, vertebral arteries, circle of Willis, and the intracranial arteries that branch off from them.

The internal carotid arteries and vertebral arteries merge to form the circle of Willis, a polygonal network of vessels located at the base of the brain. The anterior cerebral artery, middle cerebral artery, posterior cerebral artery, and communicating arteries are the major vessels that branch off from the circle of Willis and supply blood to different regions of the brain.

Interruptions or abnormalities in the cerebrovascular circulation can lead to various neurological conditions such as stroke, transient ischemic attack (TIA), and vascular dementia.

Venous thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) in the deep veins, often in the legs (deep vein thrombosis or DVT), but it can also occur in other parts of the body such as the arms, pelvis, or lungs (pulmonary embolism).

The formation of a venous thrombus can be caused by various factors, including injury to the blood vessel wall, changes in blood flow, and alterations in the composition of the blood. These factors can lead to the activation of clotting factors and platelets, which can result in the formation of a clot that blocks the vein.

Symptoms of venous thrombosis may include swelling, pain, warmth, and redness in the affected area. In some cases, the clot can dislodge and travel to other parts of the body, causing potentially life-threatening complications such as pulmonary embolism.

Risk factors for venous thrombosis include advanced age, obesity, smoking, pregnancy, use of hormonal contraceptives or hormone replacement therapy, cancer, recent surgery or trauma, prolonged immobility, and a history of previous venous thromboembolism. Treatment typically involves the use of anticoagulant medications to prevent further clotting and dissolve existing clots.

Genetic transcription is the process by which the information in a strand of DNA is used to create a complementary RNA molecule. This process is the first step in gene expression, where the genetic code in DNA is converted into a form that can be used to produce proteins or functional RNAs.

During transcription, an enzyme called RNA polymerase binds to the DNA template strand and reads the sequence of nucleotide bases. As it moves along the template, it adds complementary RNA nucleotides to the growing RNA chain, creating a single-stranded RNA molecule that is complementary to the DNA template strand. Once transcription is complete, the RNA molecule may undergo further processing before it can be translated into protein or perform its functional role in the cell.

Transcription can be either "constitutive" or "regulated." Constitutive transcription occurs at a relatively constant rate and produces essential proteins that are required for basic cellular functions. Regulated transcription, on the other hand, is subject to control by various intracellular and extracellular signals, allowing cells to respond to changing environmental conditions or developmental cues.

Lysine is an essential amino acid, which means that it cannot be synthesized by the human body and must be obtained through the diet. Its chemical formula is (2S)-2,6-diaminohexanoic acid. Lysine is necessary for the growth and maintenance of tissues in the body, and it plays a crucial role in the production of enzymes, hormones, and antibodies. It is also essential for the absorption of calcium and the formation of collagen, which is an important component of bones and connective tissue. Foods that are good sources of lysine include meat, poultry, fish, eggs, and dairy products.

Anistreplase is a thrombolytic or fibrinolytic agent, which is a type of medication that dissolves blood clots. It is a form of plasminogen activator, a enzyme that converts plasminogen to plasmin, which then breaks down the fibrin protein in blood clots. Anistreplase is used in the treatment of acute myocardial infarction (heart attack) and is administered through intravenous injection.

The medical definition of 'Anistreplase' is: "A thrombolytic agent that is a form of streptokinase-streptodornase complex, used in the management of acute myocardial infarction." (Source: Dorland's Illustrated Medical Dictionary)

Vascular patency is a term used in medicine to describe the state of a blood vessel (such as an artery or vein) being open, unobstructed, and allowing for the normal flow of blood. It is an important concept in the treatment and management of various cardiovascular conditions, such as peripheral artery disease, coronary artery disease, and deep vein thrombosis.

Maintaining vascular patency can help prevent serious complications like tissue damage, organ dysfunction, or even death. This may involve medical interventions such as administering blood-thinning medications to prevent clots, performing procedures to remove blockages, or using devices like stents to keep vessels open. Regular monitoring of vascular patency is also crucial for evaluating the effectiveness of treatments and adjusting care plans accordingly.

Emergency Medical Services (EMS) is a system that provides immediate and urgent medical care, transportation, and treatment to patients who are experiencing an acute illness or injury that poses an immediate threat to their health, safety, or life. EMS is typically composed of trained professionals, such as emergency medical technicians (EMTs), paramedics, and first responders, who work together to assess a patient's condition, administer appropriate medical interventions, and transport the patient to a hospital or other medical facility for further treatment.

The goal of EMS is to quickly and effectively stabilize patients in emergency situations, prevent further injury or illness, and ensure that they receive timely and appropriate medical care. This may involve providing basic life support (BLS) measures such as cardiopulmonary resuscitation (CPR), controlling bleeding, and managing airway obstructions, as well as more advanced interventions such as administering medications, establishing intravenous lines, and performing emergency procedures like intubation or defibrillation.

EMS systems are typically organized and managed at the local or regional level, with coordination and oversight provided by public health agencies, hospitals, and other healthcare organizations. EMS providers may work for private companies, non-profit organizations, or government agencies, and they may be dispatched to emergencies via 911 or other emergency response systems.

In summary, Emergency Medical Services (EMS) is a critical component of the healthcare system that provides urgent medical care and transportation to patients who are experiencing acute illnesses or injuries. EMS professionals work together to quickly assess, stabilize, and transport patients to appropriate medical facilities for further treatment.

Magnetic Resonance Angiography (MRA) is a non-invasive medical imaging technique that uses magnetic fields and radio waves to create detailed images of the blood vessels or arteries within the body. It is a type of Magnetic Resonance Imaging (MRI) that focuses specifically on the circulatory system.

MRA can be used to diagnose and evaluate various conditions related to the blood vessels, such as aneurysms, stenosis (narrowing of the vessel), or the presence of plaques or tumors. It can also be used to plan for surgeries or other treatments related to the vascular system. The procedure does not use radiation and is generally considered safe, although people with certain implants like pacemakers may not be able to have an MRA due to safety concerns.

"Wistar rats" are a strain of albino rats that are widely used in laboratory research. They were developed at the Wistar Institute in Philadelphia, USA, and were first introduced in 1906. Wistar rats are outbred, which means that they are genetically diverse and do not have a fixed set of genetic characteristics like inbred strains.

Wistar rats are commonly used as animal models in biomedical research because of their size, ease of handling, and relatively low cost. They are used in a wide range of research areas, including toxicology, pharmacology, nutrition, cancer, cardiovascular disease, and behavioral studies. Wistar rats are also used in safety testing of drugs, medical devices, and other products.

Wistar rats are typically larger than many other rat strains, with males weighing between 500-700 grams and females weighing between 250-350 grams. They have a lifespan of approximately 2-3 years. Wistar rats are also known for their docile and friendly nature, making them easy to handle and work with in the laboratory setting.

Phase IV clinical trials, also known as post-marketing surveillance trials or post-authorization studies, are research studies conducted after a drug or medical device has been approved for marketing and made available to the public. The primary objective of these trials is to gather additional information about the safety, efficacy, and optimal use of the product in larger and more diverse populations over a longer period of time than was possible during the initial phases of clinical development (Phases I-III).

Phase IV studies can be designed to:

1. Evaluate long-term safety and side effects: These trials monitor adverse events that may not have been detected in earlier, shorter-term studies, allowing researchers to identify rare or delayed reactions and assess the overall risk-benefit profile of the product in real-world settings.
2. Assess effectiveness in various patient populations: Phase IV trials can help determine how well a treatment works in specific groups, such as children, elderly individuals, or those with multiple medical conditions or taking other medications concurrently. This information can inform labeling changes and guide clinical decision-making.
3. Compare the product to alternative treatments: Head-to-head comparisons of different drugs or devices can help healthcare providers make evidence-based choices when selecting therapies for their patients.
4. Investigate new indications or uses: Phase IV trials may explore whether a drug or device is effective for treating additional conditions or in different dosages, formulations, or routes of administration.
5. Evaluate cost-effectiveness and value: These studies can help healthcare systems and payers understand the economic impact of a product, including its costs relative to its benefits and potential savings from improved health outcomes or reduced complications.

Phase IV clinical trials are essential for ensuring that new treatments continue to demonstrate safety and efficacy as they are used more widely in larger and more diverse populations. This information can lead to updates in labeling, guidelines, and prescribing practices, ultimately improving patient care and outcomes.

Thromboelastography (TEG) is a viscoelastic method used to assess the kinetics of clot formation, clot strength, and fibrinolysis in whole blood. It provides a global assessment of hemostasis by measuring the mechanical properties of a clot as it forms and dissolves over time. The TEG graph displays several parameters that reflect the different stages of clotting, including reaction time (R), clot formation time (K), angle of clot formation (α), maximum amplitude (MA), and percentage lysis at 30 minutes (LY30). These parameters can help guide transfusion therapy and inform decisions regarding the management of coagulopathy in various clinical settings, such as trauma, cardiac surgery, liver transplantation, and obstetrics.

Tissue adhesions, also known as scar tissue adhesions, are abnormal bands of fibrous tissue that form between two or more internal organs, or between organs and the walls of the chest or abdominal cavity. These adhesions can develop after surgery, infection, injury, radiation, or prolonged inflammation. The fibrous bands can cause pain, restrict movement of the organs, and potentially lead to complications such as bowel obstruction. Treatment options for tissue adhesions may include medication, physical therapy, or surgical intervention to remove the adhesions.

Metalloendopeptidases are a type of enzymes that cleave peptide bonds in proteins, specifically at interior positions within the polypeptide chain. They require metal ions as cofactors for their catalytic activity, typically zinc (Zn2+) or cobalt (Co2+). These enzymes play important roles in various biological processes such as protein degradation, processing, and signaling. Examples of metalloendopeptidases include thermolysin, matrix metalloproteinases (MMPs), and neutrophil elastase.

Diffusion Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses magnetic fields and radio waves to produce detailed images of the body's internal structures, particularly the brain and nervous system. In diffusion MRI, the movement of water molecules in biological tissues is measured and analyzed to generate contrast in the images based on the microstructural properties of the tissue.

Diffusion MRI is unique because it allows for the measurement of water diffusion in various directions, which can reveal important information about the organization and integrity of nerve fibers in the brain. This technique has been widely used in research and clinical settings to study a variety of neurological conditions, including stroke, traumatic brain injury, multiple sclerosis, and neurodegenerative diseases such as Alzheimer's disease.

In summary, diffusion MRI is a specialized type of MRI that measures the movement of water molecules in biological tissues to generate detailed images of the body's internal structures, particularly the brain and nervous system. It provides valuable information about the microstructural properties of tissues and has important applications in both research and clinical settings.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Fibrinopeptide A is a small protein molecule that is cleaved and released from the larger fibrinogen protein during the blood clotting process. Specifically, it is removed by the enzyme thrombin as part of the conversion of fibrinogen to fibrin, which is the main structural component of a blood clot. The measurement of Fibrinopeptide A in the blood can be used as a marker for ongoing thrombin activation and fibrin formation, which are key events in coagulation and hemostasis. Increased levels of Fibrinopeptide A may indicate abnormal or excessive blood clotting, such as in disseminated intravascular coagulation (DIC) or deep vein thrombosis (DVT).

Thromboembolism is a medical condition that refers to the obstruction of a blood vessel by a thrombus (blood clot) that has formed elsewhere in the body and then been transported by the bloodstream to a narrower vessel, where it becomes lodged. This process can occur in various parts of the body, leading to different types of thromboembolisms:

1. Deep Vein Thrombosis (DVT): A thrombus forms in the deep veins, usually in the legs or pelvis, and then breaks off and travels to the lungs, causing a pulmonary embolism.
2. Pulmonary Embolism (PE): A thrombus formed elsewhere, often in the deep veins of the legs, dislodges and travels to the lungs, blocking one or more pulmonary arteries. This can lead to shortness of breath, chest pain, and potentially life-threatening complications if not treated promptly.
3. Cerebral Embolism: A thrombus formed in another part of the body, such as the heart or carotid artery, dislodges and travels to the brain, causing a stroke or transient ischemic attack (TIA).
4. Arterial Thromboembolism: A thrombus forms in an artery and breaks off, traveling to another part of the body and blocking blood flow to an organ or tissue, leading to potential damage or loss of function. Examples include mesenteric ischemia (intestinal damage due to blocked blood flow) and retinal artery occlusion (vision loss due to blocked blood flow in the eye).

Prevention, early detection, and appropriate treatment are crucial for managing thromboembolism and reducing the risk of severe complications.

Up-regulation is a term used in molecular biology and medicine to describe an increase in the expression or activity of a gene, protein, or receptor in response to a stimulus. This can occur through various mechanisms such as increased transcription, translation, or reduced degradation of the molecule. Up-regulation can have important functional consequences, for example, enhancing the sensitivity or response of a cell to a hormone, neurotransmitter, or drug. It is a normal physiological process that can also be induced by disease or pharmacological interventions.

The basilar artery is a major blood vessel that supplies oxygenated blood to the brainstem and cerebellum. It is formed by the union of two vertebral arteries at the lower part of the brainstem, near the junction of the medulla oblongata and pons.

The basilar artery runs upward through the center of the brainstem and divides into two posterior cerebral arteries at the upper part of the brainstem, near the midbrain. The basilar artery gives off several branches that supply blood to various parts of the brainstem, including the pons, medulla oblongata, and midbrain, as well as to the cerebellum.

The basilar artery is an important part of the circle of Willis, a network of arteries at the base of the brain that ensures continuous blood flow to the brain even if one of the arteries becomes blocked or narrowed.

Transfection is a term used in molecular biology that refers to the process of deliberately introducing foreign genetic material (DNA, RNA or artificial gene constructs) into cells. This is typically done using chemical or physical methods, such as lipofection or electroporation. Transfection is widely used in research and medical settings for various purposes, including studying gene function, producing proteins, developing gene therapies, and creating genetically modified organisms. It's important to note that transfection is different from transduction, which is the process of introducing genetic material into cells using viruses as vectors.

Drug synergism is a pharmacological concept that refers to the interaction between two or more drugs, where the combined effect of the drugs is greater than the sum of their individual effects. This means that when these drugs are administered together, they produce an enhanced therapeutic response compared to when they are given separately.

Drug synergism can occur through various mechanisms, such as:

1. Pharmacodynamic synergism - When two or more drugs interact with the same target site in the body and enhance each other's effects.
2. Pharmacokinetic synergism - When one drug affects the metabolism, absorption, distribution, or excretion of another drug, leading to an increased concentration of the second drug in the body and enhanced therapeutic effect.
3. Physiochemical synergism - When two drugs interact physically, such as when one drug enhances the solubility or permeability of another drug, leading to improved absorption and bioavailability.

It is important to note that while drug synergism can result in enhanced therapeutic effects, it can also increase the risk of adverse reactions and toxicity. Therefore, healthcare providers must carefully consider the potential benefits and risks when prescribing combinations of drugs with known or potential synergistic effects.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Recombinant fusion proteins are artificially created biomolecules that combine the functional domains or properties of two or more different proteins into a single protein entity. They are generated through recombinant DNA technology, where the genes encoding the desired protein domains are linked together and expressed as a single, chimeric gene in a host organism, such as bacteria, yeast, or mammalian cells.

The resulting fusion protein retains the functional properties of its individual constituent proteins, allowing for novel applications in research, diagnostics, and therapeutics. For instance, recombinant fusion proteins can be designed to enhance protein stability, solubility, or immunogenicity, making them valuable tools for studying protein-protein interactions, developing targeted therapies, or generating vaccines against infectious diseases or cancer.

Examples of recombinant fusion proteins include:

1. Etaglunatide (ABT-523): A soluble Fc fusion protein that combines the heavy chain fragment crystallizable region (Fc) of an immunoglobulin with the extracellular domain of the human interleukin-6 receptor (IL-6R). This fusion protein functions as a decoy receptor, neutralizing IL-6 and its downstream signaling pathways in rheumatoid arthritis.
2. Etanercept (Enbrel): A soluble TNF receptor p75 Fc fusion protein that binds to tumor necrosis factor-alpha (TNF-α) and inhibits its proinflammatory activity, making it a valuable therapeutic option for treating autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
3. Abatacept (Orencia): A fusion protein consisting of the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) linked to the Fc region of an immunoglobulin, which downregulates T-cell activation and proliferation in autoimmune diseases like rheumatoid arthritis.
4. Belimumab (Benlysta): A monoclonal antibody that targets B-lymphocyte stimulator (BLyS) protein, preventing its interaction with the B-cell surface receptor and inhibiting B-cell activation in systemic lupus erythematosus (SLE).
5. Romiplostim (Nplate): A fusion protein consisting of a thrombopoietin receptor agonist peptide linked to an immunoglobulin Fc region, which stimulates platelet production in patients with chronic immune thrombocytopenia (ITP).
6. Darbepoetin alfa (Aranesp): A hyperglycosylated erythropoiesis-stimulating protein that functions as a longer-acting form of recombinant human erythropoietin, used to treat anemia in patients with chronic kidney disease or cancer.
7. Palivizumab (Synagis): A monoclonal antibody directed against the F protein of respiratory syncytial virus (RSV), which prevents RSV infection and is administered prophylactically to high-risk infants during the RSV season.
8. Ranibizumab (Lucentis): A recombinant humanized monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), used in the treatment of age-related macular degeneration, diabetic retinopathy, and other ocular disorders.
9. Cetuximab (Erbitux): A chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR), used in the treatment of colorectal cancer and head and neck squamous cell carcinoma.
10. Adalimumab (Humira): A fully humanized monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
11. Bevacizumab (Avastin): A recombinant humanized monoclonal antibody that binds to VEGF-A, used in the treatment of various cancers, including colorectal, lung, breast, and kidney cancer.
12. Trastuzumab (Herceptin): A humanized monoclonal antibody that targets HER2/neu receptor, used in the treatment of breast cancer.
13. Rituximab (Rituxan): A chimeric monoclonal antibody that binds to CD20 antigen on B cells, used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis.
14. Palivizumab (Synagis): A humanized monoclonal antibody that binds to the F protein of respiratory syncytial virus, used in the prevention of respiratory syncytial virus infection in high-risk infants.
15. Infliximab (Remicade): A chimeric monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.
16. Natalizumab (Tysabri): A humanized monoclonal antibody that binds to α4β1 integrin, used in the treatment of multiple sclerosis and Crohn's disease.
17. Adalimumab (Humira): A fully human monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
18. Golimumab (Simponi): A fully human monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
19. Certolizumab pegol (Cimzia): A PEGylated Fab' fragment of a humanized monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
20. Ustekinumab (Stelara): A fully human monoclonal antibody that targets IL-12 and IL-23, used in the treatment of psoriasis, psoriatic arthritis, and Crohn's disease.
21. Secukinumab (Cosentyx): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
22. Ixekizumab (Taltz): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis and psoriatic arthritis.
23. Brodalumab (Siliq): A fully human monoclonal antibody that targets IL-17 receptor A, used in the treatment of psoriasis.
24. Sarilumab (Kevzara): A fully human monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis.
25. Tocilizumab (Actemra): A humanized monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and chimeric antigen receptor T-cell-induced cytokine release syndrome.
26. Siltuximab (Sylvant): A chimeric monoclonal antibody that targets IL-6, used in the treatment of multicentric Castleman disease.
27. Satralizumab (Enspryng): A humanized monoclonal antibody that targets IL-6 receptor alpha, used in the treatment of neuromyelitis optica spectrum disorder.
28. Sirukumab (Plivensia): A human monoclonal antibody that targets IL-6, used in the treatment

Cycloheximide is an antibiotic that is primarily used in laboratory settings to inhibit protein synthesis in eukaryotic cells. It is derived from the actinobacteria species Streptomyces griseus. In medical terms, it is not used as a therapeutic drug in humans due to its significant side effects, including liver toxicity and potential neurotoxicity. However, it remains a valuable tool in research for studying protein function and cellular processes.

The antibiotic works by binding to the 60S subunit of the ribosome, thereby preventing the transfer RNA (tRNA) from delivering amino acids to the growing polypeptide chain during translation. This inhibition of protein synthesis can be lethal to cells, making cycloheximide a useful tool in studying cellular responses to protein depletion or misregulation.

In summary, while cycloheximide has significant research applications due to its ability to inhibit protein synthesis in eukaryotic cells, it is not used as a therapeutic drug in humans because of its toxic side effects.

Aminocaproates are a group of chemical compounds that contain an amino group and a carboxylic acid group, as well as a straight or branched alkyl chain with 6-10 carbon atoms. They are often used in medical settings as anti-fibrinolytic agents, which means they help to prevent the breakdown of blood clots.

One example of an aminocaproate is epsilon-aminocaproic acid (EACA), which is a synthetic analogue of the amino acid lysine. EACA works by inhibiting the activation of plasminogen to plasmin, which is an enzyme that breaks down blood clots. By doing so, EACA can help to reduce bleeding and improve clot stability in certain medical conditions, such as hemophilia or following surgery.

Other aminocaproates include tranexamic acid (TXA) and 4-aminoethylbenzoic acid (AEBA), which also have anti-fibrinolytic properties and are used in similar clinical settings. However, it's important to note that these medications can increase the risk of thrombosis (blood clots) if not used properly, so they should only be administered under the close supervision of a healthcare provider.

Myocardial reperfusion is the restoration of blood flow to the heart muscle (myocardium), usually after a period of ischemia or reduced oxygen supply, such as during a myocardial infarction (heart attack). This can be achieved through various medical interventions, including thrombolytic therapy, percutaneous coronary intervention (PCI), or coronary artery bypass surgery (CABG). The goal of myocardial reperfusion is to salvage the jeopardized myocardium, preserve cardiac function, and reduce the risk of complications like heart failure or arrhythmias. However, it's important to note that while reperfusion is crucial for treating ischemic heart disease, it can also lead to additional injury to the heart muscle, known as reperfusion injury.

The femoral vein is the large vein that runs through the thigh and carries oxygen-depleted blood from the lower limbs back to the heart. It is located in the femoral triangle, along with the femoral artery and nerve. The femoral vein begins at the knee as the popliteal vein, which then joins with the deep vein of the thigh to form the femoral vein. As it moves up the leg, it is joined by several other veins, including the great saphenous vein, before it becomes the external iliac vein at the inguinal ligament in the groin.

Evidence-based emergency medicine (EBEM) is a practice of emergency medical care that integrates the best available scientific evidence with clinical expertise and patient values to make informed decisions about diagnosis, treatment, and management of emergency conditions. It involves a systematic approach to critically evaluate and apply research evidence from clinical trials, observational studies, and other sources to improve patient outcomes and ensure that the care provided is based on the latest medical knowledge. EBEM also emphasizes the importance of ongoing education and continuous quality improvement to keep up with new developments in emergency medicine and to ensure that patients receive the most effective and safe care possible.

Matrix metalloproteinases (MMPs) are a group of enzymes responsible for the degradation and remodeling of the extracellular matrix, the structural framework of most tissues in the body. These enzymes play crucial roles in various physiological processes such as tissue repair, wound healing, and embryonic development. They also participate in pathological conditions like tumor invasion, metastasis, and inflammatory diseases by breaking down the components of the extracellular matrix, including collagens, elastins, proteoglycans, and gelatins. MMPs are zinc-dependent endopeptidases that require activation from their proenzyme form to become fully functional. Their activity is tightly regulated at various levels, including gene expression, protein synthesis, and enzyme inhibition by tissue inhibitors of metalloproteinases (TIMPs). Dysregulation of MMPs has been implicated in several diseases, making them potential therapeutic targets for various clinical interventions.

Melanoma is defined as a type of cancer that develops from the pigment-containing cells known as melanocytes. It typically occurs in the skin but can rarely occur in other parts of the body, including the eyes and internal organs. Melanoma is characterized by the uncontrolled growth and multiplication of melanocytes, which can form malignant tumors that invade and destroy surrounding tissue.

Melanoma is often caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds, but it can also occur in areas of the body not exposed to the sun. It is more likely to develop in people with fair skin, light hair, and blue or green eyes, but it can affect anyone, regardless of their skin type.

Melanoma can be treated effectively if detected early, but if left untreated, it can spread to other parts of the body and become life-threatening. Treatment options for melanoma include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, depending on the stage and location of the cancer. Regular skin examinations and self-checks are recommended to detect any changes or abnormalities in moles or other pigmented lesions that may indicate melanoma.

In the context of healthcare, "safety" refers to the freedom from harm or injury that is intentionally designed into a process, system, or environment. It involves the prevention of adverse events or injuries, as well as the reduction of risk and the mitigation of harm when accidents do occur. Safety in healthcare aims to protect patients, healthcare workers, and other stakeholders from potential harm associated with medical care, treatments, or procedures. This is achieved through evidence-based practices, guidelines, protocols, training, and continuous quality improvement efforts.

The Tissue-Type Plasminogen Activator Story, Collen, D., Lijnen, H.R. Genentech Press Release 1982 Tissue Plasminogen Activator ... "Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized ... Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.[citation needed] Once in the body, tPA ... Tissue-type plasminogen activators were initially identified and isolated from mammalian tissues after which a cDNA library was ...
There is a sex difference in the use of intravenous tissue plasminogen activator, as it is less likely to be used for women ... Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator ( ... Collen D, Lijnen HR (April 2004). "Tissue-type plasminogen activator: a historical perspective and personal account". Journal ... Collen D, Lijnen HR (August 2009). "The tissue-type plasminogen activator story". Arteriosclerosis, Thrombosis, and Vascular ...
There are two main plasminogen activators: urokinase (uPA) and tissue plasminogen activator (tPA). Tissue plasminogen ... The main inhibitor of tissue plasminogen activator and urokinase is plasminogen activator inhibitor-1 (PAI-1). Plasminogen ... Plasminogen activators are inhibited by plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, and protein C ... that specifically inhibits tissue plasminogen activator (tPA) and urokinase (uPA). Tissue plasminogen activator and urokinase ...
"Tissue Plasminogen Activator" (PDF). Stroke Association. The Stroke Collaborative. Archived from the original (PDF) on 28 March ... For instance, one study suggests that a tissue plasminogen activator (tPA) therapy intervention, commonly used in stroke ...
... that functions as the principal inhibitor of tissue-type plasminogen activator (tPA) and urokinase (uPA), the activators of ... Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor (serpin E1) is a protein ... Alessi MC, Poggi M, Juhan-Vague I (June 2007). "Plasminogen activator inhibitor-1, adipose tissue and insulin resistance". ... Plasminogen activator inhibitor-1 has been shown to interact with ORM1. GRCh38: Ensembl release 89: ENSG00000106366 - Ensembl, ...
ISBN 978-1-84755-735-3. Degen, S. J.; Rajput, B.; Reich, E. (May 25, 1986). "The human tissue plasminogen activator gene". The ... 26: 8270-9. PMID 2831940 Degen SJ, Rajput B, Reich E. The human tissue plasminogen activator gene. The Journal of Biological ... Degen, S. J.; Rajput, B.; Reich, E. (May 25, 1986). "The human tissue plasminogen activator gene". Journal of Biological ... Degen led a team to characterize the human tissue plasminogen activator (t-PA) gene. Human t-PA is a protein implicated in the ...
Nattokinase See Tissue plasminogen activator and Maggot therapy. Mecikoglu M, Saygi B, Yildirim Y, Karadag-Saygi E, Ramadan SS ... Tissue plasminogen activator (TPA) is a serine protease occurring in animals including humans. Human-identical TPA (produced ... "Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis". Lancet. ... Debridement involves the removal of dead or damaged tissue from wounds in order to assist healing. Much of the debris to be ...
Gordon K, Lee E, Vitale JA, Smith AE, Westphal H, Hennighausen L (1987). "Production of human tissue plasminogen activator in ... engineered to produce human tissue plasminogen activator in 1987. The first genetically modified animal to be commercialised ... Scott, B.B.; Lois, C. (2005). "Generation of tissue-specific transgenic birds with lentiviral vectors". Proc. Natl. Acad. Sci. ... The generation of transgenic protocols (whole organism, cell or tissue specific, tagged with reporter genes) has increased the ...
These medications include tissue plasminogen activator, reteplase, streptokinase, and tenecteplase. Thrombolysis is not ... Blockage of an artery can lead to tissue death in tissue being supplied by that artery. Atherosclerotic plaques are often ... Tissue death and myocardial scarring alter the normal conduction pathways of the heart and weaken affected areas. The size and ... The dead tissue is surrounded by a zone of potentially reversible ischemia that progresses to become a full-thickness ...
Gordon K, Lee E, Vitale JA, Smith AE, Westphal H, Hennighausen L (1987). "Production of human tissue plasminogen activator in ... The mice were engineered to produce human tissue plasminogen activator, a protein involved in breaking down blood clots. In ... and tissue plasminogen activator which dissolves blood clots. Outside of medicine they have been used to produce biofuels. ... Major advances in tissue culture and plant cellular mechanisms for a wide range of plants has originated from systems developed ...
2003). "Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator". Eur. J. Biochem. 270 (8): 1850-4. ... Berglund L, Petersen TE (1992). "The gene structure of tetranectin, a plasminogen binding protein". FEBS Lett. 309 (1): 15-9. ... Wewer UM, Albrechtsen R (1992). "Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in ... 1997). "Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an alpha-helical coiled coil". FEBS Lett ...
"Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen ... Antibodies that neutralize HMGB1 confer protection against damage and tissue injury during arthritis, colitis, ischemia, sepsis ... Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation". The Journal ... is a unique activator of p53". Genes & Development. 12 (4): 462-72. doi:10.1101/gad.12.4.462. PMC 316524. PMID 9472015. Milev P ...
A single, modified TEG assay with exogenous tissue plasminogen activator (tPA) demonstrated remarkable efficiency in unmasking ... "Viscoelastic Tissue Plasminogen Activator Challenge Predicts Massive Transfusion in 15 Minutes". Journal of the American ... A RapidTEG uses tissue factor in addition to kaolin thereby further speeding up the reaction. In this assay, the R-value is ...
Further thrombotic events could be treated with tissue plasminogen activator (tPA). Overdose of streptokinase or tPA can be ... Rabijns A, De Bondt HL, De Ranter C (May 1997). "Three-dimensional structure of staphylokinase, a plasminogen activator with ... When streptokinase is present, it binds to plasminogen to form a complex (streptokinase·plasminogen) that converts substrate ... Each domain binds plasminogen, although none can activate plasminogen independently. Plasmin is produced in the blood to break ...
"Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized ... Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G (Jan 2000). "Role of tissue plasminogen activator receptor LRP in ... Notably, LRP1 functions in clearing proteases such as plasmin, urokinase-type plasminogen activator, and metalloproteinases, ... "Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells". Oncotarget. 6 ...
October 2013). "Intravenous tissue plasminogen activator administration in community hospitals facilitated by telestroke ... Telepathology has been successfully used for many applications including the rendering histopathology tissue diagnoses, at a ...
In human tissue plasminogen activator chain A the FN1 domain together with the following epidermal growth factor (EGF)-like ... "Solution structure of the fibrin binding finger domain of tissue-type plasminogen activator determined by 1H nuclear magnetic ... "High resolution analysis of functional determinants on human tissue-type plasminogen activator". J. Biol. Chem. 266 (8): 5191- ... dynamics of the fibronectin type I and epidermal growth factor-like pair of modules of tissue-type plasminogen activator". ...
Ichinose A, Takio K, Fujikawa K (Jul 1986). "Localization of the binding site of tissue-type plasminogen activator to fibrin". ... Fibrinogen alpha chain has been shown to interact with tissue plasminogen activator. Fibrinogen gamma chain GRCh38: Ensembl ... fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator". The ... and plasminogen-binding sites within fibrin(ogen) alpha C-domains". Biochemistry. 40 (3): 801-808. doi:10.1021/bi001789t. PMID ...
In increasing numbers of primary stroke centers, pharmacologic thrombolysis with the drug tissue plasminogen activator (tPA), ... Smith WS (June 1, 2006). "Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic ... there is typically some blood flow to the downstream tissue through collateral blood vessels, and the tissue can typically ... 70 to 80% reduction in diameter). In tissue losses that are not immediately fatal, the best course of action is to make every ...
It increases the release of tissue plasminogen activator from brain microvascular endothelial cells. It results in an increase ... However, relative differences in perfusion do not necessarily imply any absolute decrease in blood supply in the tissue ...
Effect of tissue-plasminogen activator on leukocyte-endothelial interactions at the microcirculatory level. Plast Reconstr Surg ...
2005). "Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system". Thromb. Haemost ... Yepes M; Lawrence DA (2004). "Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous ... Barker-Carlson K; Lawrence DA; Schwartz BS (2003). "Acyl-enzyme complexes between tissue-type plasminogen activator and ... 1998). "Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. ...
... of recombinant tissue plasminogen activator (r-TPA) has been found to be effective in treating the ... Wu TT, Wang HH (January 2009). "Intracameral recombinant tissue plasminogen activator for the treatment of severe fibrin ...
Injection of tissue plasminogen activator (a fibrinolytic drug) in the CSF improved glymphatic functioning. In a parallel study ... would exceed 100 hours to traverse 1 cm of brain tissue, a rate that is not compatible with the intense metabolic demands of ... and metabolic waste products from the systemic tissues back into the blood. The efficient removal of soluble proteins from the ... brain tissue. Additionally, a clearance system based on simple diffusion would lack the sensitivity to respond rapidly to ...
"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and ... "Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and ... 1997). "A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial ... recombinant tissue plasminogen activator, rtPA). More recently, thrombolytic agents similar in structure to rtPA such as ...
Tissue plasminogen activator: Monitor patient who receive TPA for 24 hours for brain bleeds. Spinal cord injury: immobilization ...
Akassoglou, Katerina; Kombrinck, Keith W.; Degen, Jay L.; Strickland, Sidney (2000-05-29). "Tissue Plasminogen Activator- ... Akassoglou's lab was centered around exploring neurovascular regulation of inflammation and tissue repair in the context of ...
"Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier". Journal of ... Vries later found that monocyte diapedesis into the brain during inflammation is mediated by tissue-type plasminogen activator ...
"S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme". Proc Natl ... NO carried by an invariant hemoglobin cysteine residue is essential for oxygen delivery to tissues through vasodilation of the ... The SNO-hemoglobin content of RBCs is low in multiple clinical conditions characterized by microvascular dysfunction and tissue ...
"Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier". Journal of ... Microvessels in periplaque areas coexpressed HLA-DR and VCAM-1, some others HLA-DR and urokinase plasminogen activator receptor ... The low level of uric acid found in people with MS is manifestedly causative rather than a tissue damage consequence in the ... Four different damage patterns have been identified in patient's brain tissues. The original report[citation needed] suggests ...
The Tissue-Type Plasminogen Activator Story, Collen, D., Lijnen, H.R. Genentech Press Release 1982 Tissue Plasminogen Activator ... "Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized ... Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.[citation needed] Once in the body, tPA ... Tissue-type plasminogen activators were initially identified and isolated from mammalian tissues after which a cDNA library was ...
The best-known function of the serine protease tissue-type plasminogen activator (tPA) is as a thrombolytic enzyme. However, it ... or plasminogen-deficient mice. These data show that tPA can act as an endogenous neuroprotectant in the murine hippocampus. ...
Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.[citation needed] ... "Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized ... Tissue-type plasminogen activators were initially identified and isolated from mammalian tissues after which a cDNA library was ... "Tissue Plasminogen Activator (tPA)". diapharma.com. Retrieved 2017-12-10.. *↑ 30.0 30.1 Gravanis I, Tsirka SE (February 2008). ...
Quantitative Measurement of Plasminogen Activator Activity in Rat Renal Cortical Tissue E.H.F. McGale; E.H.F. McGale ... Quantitative Measurement of Plasminogen Activator Activity in Rat Renal Cortical Tissue. Clin Sci (Lond) 1 January 1985; 68 ( ...
Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. ... Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. ...
Tissue plasminogen activator (tPA) thrombolysis, remains to be the only United States Food and Drug Administration (FDA) ... Tissue plasminogen activator (tPA) thrombolysis, remains to be the only United States Food and Drug Administration (FDA) ... a potential indicator for hemorrhagic transformation following tissue plasminogen activator (tPA) thrombolysis? Curr Neurovasc ...
Intravenous Recombinant Tissue Plasminogen Activator Therapy for Stroke Patients Receiving Maintenance Hemodialysis: The Stroke ... Background: To examine the therapeutic effect of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for ... Intravenous Recombinant Tissue Plasminogen Activator Therapy for Stroke Patients Receiving Maintenance Hemodialysis: The Stroke ... Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and ...
... is there a role for tissue plasminogen activator (tPA)? If so, Regarding anticoagulation strategies, is there a role for tissue ... plasminogen activator (tPA)? If so, what is the indication for it and who would you use it on?. Questions from social media, ...
TNF-. TF, tissue factor; PAI-1, plasminogen activator inhibitor 1; Ctrl, control; BAY, BAY11-7082. ... BAY11‑7082 inhibits the expression of tissue factor and plasminogen activator inhibitor‑1 in type‑II alveolar epithelial cells ... TF, tissue factor; PAI-1, plasminogen activator inhibitor 1; ctrl, control; BAY, BAY11-7082. ... inhibits the expressions of tissue factor (TF) and plasminogen activator inhibitor‑1 (PAI‑1) in AECⅡ in response to TNF‑α. Rat ...
Plasminogen Activation * Plasminogen & Plasmin * Plasminogen Activator Inhibitor (PAI) * Tissue Plasminogen Activator (tPA) ...
S45-7 Gastrodia-Uncaria water extract and tissue plasminogen activator for treating embolus-induced cerebral ischaemia: ... and maintenance of brain tissue integrity.. 2. Intravascular administration of tissue plasminogen activator is well tolerated ... Gastrodia-Uncaria water extract and tissue plasminogen activator for treating embolus-induced cerebral ischaemia: abridged ... which may reduce the risk of tissue plasminogen activator-induced intracranial haemorrhage. ...
Tag: recombinant tissue plasminogen activator. Polyethylene Glycol Fusion of Nerve InjuriesPolyethylene Glycol Fusion of Nerve ... technology recombinant inbred recombinant meaning recombinant plasmid recombinant rna recombinant technology recombinant tissue ...
The genes encoding the two plasminogen activators, tissue plasminogen activator and urokinase, were mapped to mouse chromosomes ... Tissue plasminogen activator and urokinase cosegregated with mouse chromosomes 8 and 14, respectively. The plasminogen ... Chromosomal assignments of genes for tissue plasminogen activator and urokinase in mouse.. ... activator genes thus fall into two syntenic groups that are conserved in human and mouse. ...
Plasminogen and Tissue Plasminogen Activator Antigen answers are found in the Daviss Lab & Diagnostic Tests powered by Unbound ... Plasminogen_Activator_Antigen. Van Leeuwen AMA, Bladh MLM. Plasminogen and Tissue Plasminogen Activator Antigen. Daviss Lab & ... Plasminogen_Activator_Antigen. Van Leeuwen AMA, Bladh MLM. Plasminogen and Tissue Plasminogen Activator Antigen [Internet]. In ... "Plasminogen and Tissue Plasminogen Activator Antigen." Daviss Lab & Diagnostic Tests, 7th ed., F.A. Davis Company, 2017. ...
Fibrinolytic agents such as tissue plasminogen activator (tPA) and streptokinase (SK) are important drugs for the treatment of ... Preparation, in vivo properties and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and ... Preparation, in vivo properties and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and ... Preparation, in vivo properties and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and ...
It is thought that the clot-specific activity of tissue plasminogen activator, used in the treatment of acute myocardial ... It is thought that the clot-specific activity of tissue plasminogen activator, used in the treatment of acute myocardial ... Ruptured Arteriovenous Malformation Complicating Thrombolytic Therapy With Tissue Plasminogen Activator. Jacqueline Proner, MD ... The incidence of intracerebral hemorrhage complicating the use of tissue plasminogen activator has been estimated to be 0.68%. ...
Tissue plasminogen activator and risk of mycardial infarction. J.G. van der Bom, P. de Knijff, F. Haverkate, M.L. Bots, P. ... Tissue plasminogen activator and risk of mycardial infarction. / Bom, J.G. van der; Knijff, P. de; Haverkate, F. et al. ... title = "Tissue plasminogen activator and risk of mycardial infarction",. author = "Bom, {J.G. van der} and Knijff, {P. de} and ... Tissue plasminogen activator and risk of mycardial infarction. In: Circulation. 1997 ; Vol. 95. blz. 2623-2627. ...
Tissue plasminogen activator. An imbalance of the clot dissolving enzymes (eg, tissue plasminogen activator [tPA]) and their ... How do tissue plasminogen activators affect the risk for coronary artery disease (CAD)? ... plasminogen activator inhibitor-1 [PAI-1]) may predispose individuals to myocardial infarctions. ... 56] chronic inflammatory diseases affecting connective tissues (eg, lupus, rheumatoid arthritis), [4, 5] human immunodeficiency ...
Tissue plasminogen activator (tPA) is the only stroke drug that actually breaks up a blood clot. Its used as a common ...
Bradykinin induction of intravascular tissue plasminogen activator. / Smith, D.; Gilbert, M.; Harmon, J. et al. In: Federation ... Smith D, Gilbert M, Harmon J, Owen W. Bradykinin induction of intravascular tissue plasminogen activator. Federation ... Smith, D., Gilbert, M., Harmon, J., & Owen, W. (1984). Bradykinin induction of intravascular tissue plasminogen activator. ... Smith, D, Gilbert, M, Harmon, J & Owen, W 1984, Bradykinin induction of intravascular tissue plasminogen activator, ...
... ... "Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation." ... "Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation." ... Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. ...
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series ... COVID-19; acute respiratory distress syndrome (ARDS); case report; fibrinolysis; tissue plasminogen activator (tPA) ... Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory dis ... Tissue Plasminogen Activator / Coronavirus Infections / Fibrinolysis / Fibrinolytic Agents / Betacoronavirus Type of study: ...
The plasminogen/plasmin system has an important impact on this process, particularly by degradin … ... tissue and urokinase-type plasminogen activators and plasminogen/plasmin in the cases of corneal ulcers and thermal or chemical ... tissue and urokinase-type plasminogen activators and plasminogen/plasmin in the tear fluid of control subjects and patients ... Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair Exp Eye ...
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more ...
Chemicals/CAS: plasminogen activator, 9039-53-6; Isoflurophate, 55-91-4; Plasminogen Activators, EC 3.4.21.-; Plasminogen ... Purification and partial characterization of plasminogen activator from human uterine tissue. Title Purification and partial ... A procedure was developed for the purification of a plasminogen activator from human uterine tissue. It involves six ... extraction of the plasminogen activator from delipidated uterine tissue with 0.3 M potassium acetate buffer, pH 4.2; ammonium ...
... L. Jay Katz ... Recombinant tissue plasminogen activator (rTPA) in ophthalmology has been used in the treatment of hyphema [1] and fibrin ... Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants Arch Ophthalmol ... Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery J Cataract Refract Surg ...
Tissue Plasminogen Activator (t-PA or tPA). t-PA is a protein involved in the breakdown of blood clots. t-PA is used in some ... Tissue Plasminogen Activator. Transient Ischemic Attack (TIA). A transient ischemic attack or TIA is a condition that is ... It works by stimulating secondary fibrinolysis by plasmin through infusion of analogs of tissue plasminogen activator (tPA), ... The high density lipoproteins transport cholesterol from the tissues of the body to the liver so it can be eliminated in the ...
Recombinant Tissue Plasminogen Activator (rt-PA). Common name: Alteplase. Rt-PA is used to treat ischemic stroke. Other clot- ...
  • tPA can be manufactured using recombinant biotechnology techniques, producing types of recombinant tissue plasminogen activator (rtPA) such as alteplase, reteplase, and tenecteplase. (wikipedia.org)
  • tPA produced by such means are referred to as recombinant tissue plasminogen activator ( rtPA ). (wikidoc.org)
  • Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. (bmj.com)
  • To examine the therapeutic effect of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for stroke patients receiving maintenance hemodialysis (HD). (karger.com)
  • An anterior chamber injection of 0.1 ml recombinant tissue plasminogen activator (25 mcg/0.1 mL) was performed to improve the trabecular meshwork outflow facility compromised secondary to fibrin blockade. (openophthalmologyjournal.com)
  • tPA created this way may be referred to as recombinant tissue plasminogen activator (rtPA). (magnusconferences.com)
  • Because a previous study utilizing a combination of recombinant tissue-type plasminogen activator (rt-PA) and urokinase demonstrated reduced reocclusion rates compared with rates obtained with rt-PA alone, this study was conducted to determine whether the combination of rt-PA and streptokinase might achieve similar results at reduced cost. (uky.edu)
  • Urokinase type plasminogen activator receptors are soluble as biomarker response treatment in childhood tuberculosis. (urokinases.com)
  • Abcam's Urokinase type Plasminogen Activator Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Urokinase type Plasminogen Activator (uPA) in plasma, serum, urine, milk, cell culture supernatants and tissue extracts. (abcam.com)
  • A Urokinase type Plasminogen Activator specific antibody has been precoated onto 96-well plates and blocked. (abcam.com)
  • Standards or test samples are added to the wells and subsequently a Urokinase type Plasminogen Activator specific biotinylated detection antibody is added and then followed by washing with wash buffer. (abcam.com)
  • The density of yellow coloration is directly proportional to the amount of Urokinase type Plasminogen Activator captured in plate. (abcam.com)
  • In a recent pooled analysis of randomized clinical trials (RCTs), intravenous tissue plasminogen activator (TPA) improves the outcome in patients aged ≥80 years. (j-stroke.org)
  • However, very elderly patients were excluded from or substantially under-represented in earlier intravenous tissue-plasminogen activator (TPA) trials [ 7 - 11 ]. (j-stroke.org)
  • Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. (qxmd.com)
  • The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived. (elsevierpure.com)
  • Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. (bvsalud.org)
  • Intrinsically, ischemic stroke indicates the cascade of congesting events, i.e., thrombus formation and embolism, that ultimately decreases the local blood flow and cause oxygen deprivation in affected brain tissue. (hindawi.com)
  • Proner J , Rosenblum BR , Rothman A. Ruptured Arteriovenous Malformation Complicating Thrombolytic Therapy With Tissue Plasminogen Activator. (jamanetwork.com)
  • The most commonly used drug for thrombolytic therapy is tissue plasminogen activator (tPA), but other drugs can do the same thing. (medlineplus.gov)
  • Thrombolytic therapy using tissue plasminogen activator (tPA) can reduce the burden of stroke, but the short-time window for safe and effective treatment is a limiting factor [2] . (eg.net)
  • 2. Intravascular administration of tissue plasminogen activator is well tolerated with oral administration of Gastrodia-Uncaria water extract, which may reduce the risk of tissue plasminogen activator-induced intracranial haemorrhage. (hkmj.org)
  • The MIST2 study demonstrated that intrapleural administration of tissue plasminogen activator (t-PA) and DNase, or t-PA alone increased the volume of drained PF. (ox.ac.uk)
  • The aim of this study is to determine the clinical response, side effects and outcome of targeted intra-arterial administration of tissue plasminogen activator (a blockage dissolving drug) as a treatment of ATE in cats. (everycat.org)
  • It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. (wikipedia.org)
  • As an enzyme , it catalyzes the conversion of plasminogen to plasmin , the major enzyme responsible for clot breakdown. (wikidoc.org)
  • Heparin sulfate and the less sulfated glycosaminoglycan heparan sulfate enhance human plasminogen (Pg) conversion to plasmin by tissue-type plasminogen activator (t-PA). (duke.edu)
  • The plasminogen/plasmin system has an important impact on this process, particularly by degrading the extracellular matrix components with resulting interference of the repair processes. (nih.gov)
  • This paper presents the immunoblotting analysis of fibronectin, tissue and urokinase-type plasminogen activators and plasminogen/plasmin in the tear fluid of control subjects and patients affected by various ocular pathologies (corneal ulcers, thermal or chemical burns, herpetic keratitis). (nih.gov)
  • A significant modification was noted in the protein profiles of fibronectin, tissue and urokinase-type plasminogen activators and plasminogen/plasmin in the cases of corneal ulcers and thermal or chemical burns relative to the pattern observed in the control subjects, while in cases of herpetic keratitis, only plasminogen/plasmin showed slight variations. (nih.gov)
  • Fibrin-bound plasminogen will be converted by thrombolytic drugs to plasmin, the rate-limiting step in thrombolysis. (medscape.com)
  • The thrombolytic agents available today are serine proteases that work by converting plasminogen to the natural fibrinolytic agent plasmin. (medscape.com)
  • [ 1 ] Unlike streptokinase, urokinase is not antigenic and directly activates plasminogen to form plasmin. (medscape.com)
  • The ability of these substances to catalyze the conversion of plasminogen to plasmin is affected only slightly by the presence or absence of local fibrin clot. (medscape.com)
  • Specifically cleave the zymogen plasminogen to form the active enzyme plasmin. (abcam.com)
  • Scatchard plot analysis revealed one binding mechanism with a Kd value of 7 × 107 M. Conversion of H. pylori cell-bound plasminogen to plasmin in the presence of a tissue-type plasminogen activator was demonstrated by digestion of the chromogenic substrate S-2251. (lu.se)
  • Formation of H. pylori cell surface-bound plasmin may be important to provide a powerful proteolytic mechanism for gastric tissue penetration in type B gastritis and peptic ulcer disease, since plasmin degrades not only fibrin but also extracellular matrix proteins such as various collagens and fibronectin. (lu.se)
  • The aim of the present study was to determine whether BAY11‑7082, an inhibitor of the NF‑κB pathway, inhibits the expressions of tissue factor (TF) and plasminogen activator inhibitor‑1 (PAI‑1) in AECⅡ in response to TNF‑α. (spandidos-publications.com)
  • Pulmonary inflammation can damage pulmonary vascular endothelial cells and type-II alveolar epithelial cells (AECII), which further increases the expression of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) in these cells, thus activating the exogenous coagulation system. (spandidos-publications.com)
  • In conjunction with inflammation, changes in tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) have been associated with increased risk of cardiovascular disease. (cdc.gov)
  • Plasminogen activator inhibitor-1 (PAI-1) testing is indicated for unexplained mild-to-moderate delayed bleeding disorders, typically associated with trauma or surgery. (medscape.com)
  • Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein (molecular weight, 47 kDa) that is synthesized in endothelial cells, hepatocytes, and adipocytes. (medscape.com)
  • Plasminogen activator inhibitor type 1 deficiency. (medscape.com)
  • Method: Chromogenic for plasminogen activity and enzyme-linked immunosorbent for plasminogen activator antigen. (unboundmedicine.com)
  • Nursing Central , nursing.unboundmedicine.com/nursingcentral/view/Davis-Lab-and-Diagnostic-Tests/425033/all/Plasminogen_and_Tissue_Plasminogen_Activator_Antigen. (unboundmedicine.com)
  • Plasminogen binding to H. pylori seems to be independent of culture media and independent of the presence of the cytotoxin-associated CagA antigen. (lu.se)
  • It is thought that the clot-specific activity of tissue plasminogen activator, used in the treatment of acute myocardial infarction, makes bleeding complications less common than does the use of either streptokinase or urokinase. (jamanetwork.com)
  • Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. (wikipedia.org)
  • Tissue plasminogen activator (abbreviated tPA or PLAT ) is a protein involved in the breakdown of blood clots . (wikidoc.org)
  • This intrascleral micro-implant with Tissue plasminogen activator (abbreviated tPA or PLAT), contains is a protein involved in the breakdown of blood clots. (magnusconferences.com)
  • Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection. (urokinases.com)
  • Kinetics from late urokinase plasminogen activator receptors (Supar) in cirrhosis. (urokinases.com)
  • Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo. (bb-c.fr)
  • Hypercoagulability and fibrinolytic inhibition, either systemic or in lung tissue, are important characteristics of acute respiratory distress syndrome (ARDS) ( 1-4 ). (spandidos-publications.com)
  • it inhibits tissue-type plasminogen activators (tPA) and urokinase-type plasminogen activators (uPA). (medscape.com)
  • The best-known function of the serine protease tissue-type plasminogen activator (tPA) is as a thrombolytic enzyme. (jci.org)
  • 1. The treatment potential of Gastrodia-Uncaria water extract on cerebral ischaemia was demonstrated in terms of reduction of brain infarct volume of the brain, improvement of the motor behaviour recovery, stimulation of anti-oxidative enzyme, inhibition of matrix metalloproteinase, induction of neurotrophins, and maintenance of brain tissue integrity. (hkmj.org)
  • In vitro and in vivo studies evidenced CPR increase in inflamed tissues 11 , atherosclerotic vases 17 , and blood plasma of PD patients 27 . (bvsalud.org)
  • Treatment with urokinase or plasminogen activator Network (T-PA) in relation to DNASE through chest tubes has been effective in reducing the need for operation. (urokinases.com)
  • The specific activity of the final plasminogen activator preparation was increased by a factor 4500 as compared with the crude extract. (tno.nl)
  • At the site of injury, tissue factor (TF) and factor VIIa activate factors X and IX. (medscape.com)
  • Early ischemic blood brain barrier damage: a potential indicator for hemorrhagic transformation following tissue plasminogen activator (tPA) thrombolysis? (nih.gov)
  • Other medicines, surgery, or procedures may be needed to stop the bleeding from hemorrhagic stroke and save brain tissue. (cdc.gov)
  • This is a report of the rupture of an intracranial arteriovenous malformation complicating the use of tissue plasminogen activator therapy. (jamanetwork.com)
  • Scholars@Duke publication: Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. (duke.edu)
  • Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. (bvsalud.org)
  • Tissue plasminogen activator (tPA) thrombolysis, remains to be the only United States Food and Drug Administration (FDA) approved treatment for acute ischemia stroke. (nih.gov)
  • Data collected shows that the activity of the urokinase plasminogen activator, even though it has extracellular proteases, it does not need to lead to reprogramming the epithelial-mesenchymal and increased cell migration but can have different results depending on the intracellular environment. (urokinases.com)
  • Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator . (bvsalud.org)
  • The molecular weight of the plasminogen activator was 64,000 as estimated by gel filtration in 1.0 M NaCl and 69,000 as estimated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulphate. (tno.nl)
  • Kubal C, Mangus R, Fridell J, Wingler M, Nagai S, Ekser B, Tector J. Ischemic Cholangiopathy Following Liver Transplantation from Donation After Circulatory Death Donors: Role of Tissue Plasminogen Activator Flush [abstract]. (atcmeetingabstracts.com)
  • article{647bc080-7535-4010-966a-3d1fad12c300, abstract = {{The binding of iodine-labelled plasminogen to Helicobacter pylori CCUG 17874 was characterized. (lu.se)
  • A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. (bvsalud.org)
  • We also found that IPC in vivo increased tPA activity in the cornu ammonis area 1 (CA1) layer and Akt phosphorylation in the hippocampus, as well as ischemic tolerance in wild-type but not tPA- or plasminogen-deficient mice. (jci.org)
  • No activation was noted when plasminogen or tissue-type plasminogen activator was incubated with H. pylori cells alone. (lu.se)
  • Immunoblot analysis identified two plasminogen binding proteins of 57 and 42 kDa. (lu.se)
  • Whole blood and tissues were harvested for analysis of mRNA transcripts related to inflammation and coagulation. (cdc.gov)
  • The late urokinase plastinogenic activator receptor is related to liver and fibrosis inflammation and has been advised to participate in the development of liver cirrhosis. (urokinases.com)
  • To prevent IC in DCD liver transplants, we incorporated thrombolytic aortic flush using tissue-plasminogen activator (TPA) prior to cold preservation. (atcmeetingabstracts.com)
  • Human liver tissue. (caslab.com)
  • Mini-plasminogen caused total inhibition of the plasminogen binding, while the other fragments caused only partial inhibition. (lu.se)
  • The plasminogen activator genes thus fall into two syntenic groups that are conserved in human and mouse. (nih.gov)
  • A procedure was developed for the purification of a plasminogen activator from human uterine tissue. (tno.nl)
  • Tissue plasminogen activator (tPA) is the only stroke drug that actually breaks up a blood clot. (healthline.com)
  • For instance, thrombolytic agents such as tissue plasminogen activator (tPA) exhibit limited or no physical recovery of patients suffering from stroke [ 6 , 7 ]. (hindawi.com)
  • These findings suggest that H. pylori binds specifically the fifth kringle structure of the plasminogen molecule. (lu.se)
  • To increase the number of patients who are eligible to receive tissue plasminogen activator, measures are needed to reduce the prehospital and inhospital delay time. (eg.net)
  • Inhibition of the binding was observed after preincubation of H. pylori cells with nonradiolabelled plasminogen, lysine, or the lysine analogue -aminocaproic acid. (lu.se)
  • Plasminogen activity in newborns is half of adult ranges. (unboundmedicine.com)
  • and show an increase in the activity of the urokinase plasminogen activity. (urokinases.com)